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Abstract 
Arginine deiminase (ADI) is a therapeutic enzyme for cancer therapy of arginine-auxotrophic 
tumors. Despite its promising therapeutic potential, ADI’s application as anti-cancer drug is 
hampered by its low activity towards arginine under physiological conditions, mainly due to its 
high ‘KM’ (S0.5) values which are often one order of magnitude higher than the arginine 
concentration in blood plasma (0.10-0.12 mM). 
Previous directed evolution campaigns carried out in Prof. Schwaneberg group were conducted 
with the aim of boosting activity of PpADI (ADI from Pseudomonas plecoglossicida, kcat = 0.18 s
-1; 
S0.5 = 1.30 mM), and yielded variant PpADI M6 with reduced S0.5 values (S0.5 = 0.81 mM; kcat = 
11.64 s-1). In order to further reduce the S0.5 value and to increase the activity of PpADI at 
physiological arginine concentration, it was essential to develop high-throughput and sensitive 
screening system to obtain improved PpADI variants by directed evolution for in vivo 
applications in which the substrate concentration is at micromolar (µM) level. Therefore, this 
PhD thesis was focused on methodological advancements in screening systems for directed 
PpADI evolution at physiological arginine concentrations (100-120 µM in blood plasma), loop 
engineering and molecular dynamics (MD) simulations to study the structure-function 
relationship of identified beneficial positions for reducing the ‘KM’ (S0.5) value of PpADI, and 
surface engineering to improve PEGylation efficiency for prolonging half-life of PpADI in serum.  
In this project, as a first step, a sensitive screening system based on ammonia detection in 96-
well microtiter plate (MTP) format to reliably detect ≥0.005 mM ammonia was developed. After 
screening ~5,500 clones with the ammonia detection system (ADS) in two rounds of random 
mutagenesis combined with site-directed mutagenesis (SDM), variant M19 with increased kcat 
value (21.1 s-1; 105.5-fold higher compared to wild type (WT)) and reduced S0.5 value (0.35 mM 
compared to 0.81 mM (M6) and 1.30 mM (WT)) was identified. Improved performance of M19 
for inhibiting tumor growth was validated by determining IC50 values (the half maximal 
inhibitory concentration) for two melanoma cell lines. The IC50 value for SK-MEL-28 dropped 
from 8.67 µg/mL (WT) to 0.10 µg/mL (M6) to 0.04 µg/mL (M19); the IC50 values for G361 
dropped from 4.85 µg/mL (WT) to 0.12 µg/mL (M6) to 0.05 µg/mL (M19).  
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Secondly, a ligand-mediated eGFP-expression system (LiMEx) was developed as a novel flow 
cytometry based screening platform which relies on a competitive conversion/binding of 
arginine between arginine deiminase and arginine repressor (ArgR). The principle of LiMEx was 
validated by evolving PpADI for improved activity at physiological concentration of arginine and 
for more efficient inhibition of tumor growth. After screening of ~8.2×106 clones in three 
iterative rounds of epPCR libraries, PpADI variant M31 with reduced S0.5 value (0.17 mM 
compared to 1.23 mM (WT)) and, importantly, increased activity at physiological arginine 
concentration (M31: 6.14 s-1; WT: not detectable) was identified. Moreover, M31 showed a 
significant inhibitory effect against SK-MEL-28 and G361 melanoma cell lines (IC50 = 0.02 µg/mL 
for SK-MEL-28 and G361). 
Furthermore, loop engineering and molecular dynamics (MD) simulations were performed to 
study the structure-function relationship of identified beneficial positions and a gating residue 
Arg400 for reducing the ‘KM’ (S0.5) value of PpADI. Position 400 was identified to play an 
important role for the substrate affinity of PpADI which is attributable to its local flexibility. Two 
loop saturation mutagenesis libraries (multiple site saturation mutagenesis at positions 
identified from the previous directed evolution campaigns) and three site saturation 
mutagenesis (SSM) libraries were screened, and the subsequent MD simulation analysis was 
performed to identify beneficial positions for modulation of substrate affinity. Additionally, 
variants L6 (M6+R400M+D43S) and L10 (M31+R400M+D43S) exhibited lower S0.5 values (0.19 
mM and 0.17 mM, respectively). Furthermore, the possible amino acid types at position 43 for 
PpADIs’ activity were also investigated. 
Lastly, surface engineering of PpADI was carried out for PEGylation with higher efficiency and 
for enhanced stability. A new strategy for increasing the PEGylation sites was developed. The 
validation of this strategy was performed on selection of potential PEGylation sites of PpADI 
M31. After three steps in silico calculations, four Arg residues on the surface of PpADI M31 were 
finally selected and mutated to Lys having primary amines for PEGylation. Two out of four 
substitutions (R299K and R382K) contributed to enhanced thermostability of PEG-PpADI in 
human serum. The average numbers of PEGylation sites were increased from ~12 (PpADI M31) 
Abstract 
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to ~20 (PpADI M36, the final variant combined substitutions of R299K and R382K). Importantly, 
the final variant PEG-PpADI M36 exhibited improved thermal stability of Tm values (PpADI M36: 
40 °C; PEG-PpADI M31: 54 °C; PEG-PpADI M36: 64 °C), and half-life values (PpADI M36: 1.9 days; 
PEG-PpADI M31: 3.2 days; PEG-PpADI M36: 4.8 days) in human serum. This proved that the 
thermal resistance of PpADI can be improved by increasing the PEGylation efficiency via protein 
engineering. The final PEGylated PpADI variant M36 constitutes a highly attractive candidate for 
the treatment of arginine-auxotrophic tumors.  
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1. Chapter I: Introduction 
1.1. Arginine deiminase (ADI)  
Arginine deiminase (ADI, EC 3.5.3.6) catalyzes the hydrolysis of L-arginine to L-citrulline and 
ammonia. This enzyme is classified in the guanidino group-modifying enzyme (GME) 
superfamily, as it acts on carbon-nitrogen bonds other than peptide bonds, specifically in linear 
amidines. The reaction catalyzed by ADI is the first step of arginine dihydrolase pathway (ADI 
pathway, Figure 1) (Zuniga et al. 2002). Arginine is first deiminated to form citrulline by arginine 
deiminase. Secondly, the resulting citrulline is then converted to carbamoyl phosphate and 
ornithine by ornithine transcarbamylase (OTC, EC 2.1.3.3); finally, the carbamoyl phosphate is 
used to phosphorylate ADP by carbamate kinase (CK, EC 2.7.2.2), producing one ATP molecule. 
 
Figure 1. The ADI reaction (green box) and the ADI pathway (grey box). ADI: arginine deiminase; OTC: ornithine 
transcarbamylase; CK: carbamate kinase. 
1.1.1. ADIs in Nature 
ADIs are widely spread among prokaryotic organisms, however only few ADI genes have been 
found in eukaryotes. The first report of ADI (ADI from Bacillus pyocyaneus) was published in 
1933 by F. Horn's (Horn 1933); later several ADI genes have been identified, purified and 
characterized from different sources. Up to now, ADIs have been found in Pseudomonas, 
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Mycoplasma, Halobacteria, Lactococcus lactis, Streptococcus sanguis, Giardia intestinalis and so 
on (Ni et al. 2008). Table 1 summarizes the enzyme subunits, specific activity, kinetic properties 
and optimum pH/temperature of known ADIs. 
Table 1. Enzymatic properties of the reported ADIs. 
Sources 
 
Subunits 
 
Mw 
(kDa) 
Expression vector/ 
Host 
Optimum 
pH/ 
Temperature 
Km  
(mM) 
Activity 
(IU/mg) 
 
Reference 
Halobacterium 
saliniarium 
homodimer 105 NE 7.6/ 40°C - - (Monstadt and 
Holldorf 1991) 
Mycoplasma 
arthritidis 
 49 NE 7.2/ 25°C 0.004 18 (Smith et al. 
1978) 
Giardia 
intestinalis 
dimer 124 NE   41 (Knodler et al. 
1997) 
Pseudomonas 
putida 
homodimer 120 NE 6.0/ 50°C 0.2 58.8 (Shibatani et 
al. 1975) 
Lactococcus 
lactis ssp. 
homodimer 138 pGEM-T Easy / 
 E. coli BL21(DE3) 
7.2/ 60°C 8.67± 
0.045 
140.27 (Kim et al. 
2007) 
Giardia 
intestinals 
dimer 140 pQE-30/  
E. coli M15 
 - 36.5 (Knodler et al. 
1998) 
Mycoplasma 
arginini 
dimer 90 pET32a (+) / 
E. coli  NovaBlue 
6.4/ 42°C 0.37± 
0.05 
- (Noh et al. 
2002) 
Mycoplasma 
penetrans 
dimer 90 - - - - (Misawa et al. 
1994) 
Mycoplasma 
arginini 
dimer 90 pMK2/  
E. coli  JM 101 
- - 33.6 (Misawa et al. 
1994) 
Pseudomonas 
aeruginosa 
tetramer 184 pET30b / 
E. coli BL21(DE3) 
- - - (Oudjama et al. 
2002) 
Pseudomonas 
aeruginosa 
tetramer 184 pET100/  
E. coli BL21(DE3) 
~5.6/- 0.14 - (Lu et al. 2006) 
Pseudomonas 
plecoglossicida 
tetramer 184 pET42/  
E. coliBL21(DE3) 
~7.4/- 0.81(S0.5) - (Zhu et al. 
2010b) 
Streptococcus 
sanguis 
tetramer - pUC19/  E. coli  
JM83 
- - 0.115 (Burne et al. 
1989) 
 
1.1.2. ADIs’ structures  
The first ADI crystal was diffracted by Kakimoto et al. (Kakimoto et al. 1971) through multiple-
step chromatography followed by crystallization in 1970s. Almost three decades later, two X-ray 
crystal structures of ADIs were solved to understand the relationship between protein structure 
and its catalytic function. One ADI was from Mycoplasma arginini, MaADI (Figure 2, PDB code: 
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1LXY) (Das et al. 2004) and the other derived from Pseudomonas aeruginosa, PaADI (Figure 3, 
PDB codes: 1RXX and 2A9G) (Galkin et al. 2004; Galkin et al. 2005). These two ADIs share 
sequence identity of only 27% but identical catalytic triad Cys-His-Glu/Asp, which is also 
conserved in other members of the GME enzyme superfamily. MaADI was crystallized as a 
homodimer per asymmetric unit. It has a catalytic domain containing five helices and its 
catalytic triad is built by residues Cys398-His269-Glu213. The structures of MaADI revealed a 
buried and compact substrate binding pocket that is located approximately in the center of the 
MaADI structure (Figure 2). A small solvent access channel, indicated by a red arrow in Figure 
2b, leads from the binding pocket to the surface of the enzyme. The opening of the channel is 
located adjacent to the dimer interface region, which is at the opposite side of the 5-fold 
pseudosymmetric moiety of ADI. The shape and size of the access channel as observed in the 
crystal would not permit transport of the substrate, L-arginine and the product, L-citrulline, in 
and out of the pocket. Therefore, the occurrence of "closed" and "open" form was suggested to 
be dependent on substrate binding. 
The crystal structure of PaADI with arginine shows a tetrametric structure containing a total of 
1,630 amino acid residues and 492 water molecules (Figure 3a) (Galkin et al. 2004). PaADI 
tetramer, 83% amino acid sequence identity with PpADI (ADI from Pseudomonas 
plecoglossicida), is one of the largest enzyme of its structural superfamily. The overall fold of 
ADI consists of five modules in cyclical arrangement and the helical domain mediates the 
formation of tetramers. Similar to MaADI, the catalytic triad of PaADI is Cys406-His278-Glu224. 
Especially the active site of ADI is "strikingly enriched" with charged residues, which contains 
only one hydrophobic residue (Phe-163) and a Cys-406 with deprotonation state (Galkin et al. 
2005). However, Zhihong Ke and Hua Guo proposed the protonation state of the Cys 
nucleophile in PaADI and its impact on the catalysis by using quantum mechanical/molecular 
mechanics (QM/MM) models and environmental and entropic effects (Ke et al. 2011). The 
reaction free-energy barriers along with other data (e.g. experimental kcat) suggest that the Cys 
nucleophile is dominated by its protonated state in the enzyme-substrate complex, and the 
reaction barrier corresponds largely to its deprotonation. The known functions of important 
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residues are shown in Table 2, and the interactions between important residues and substrate 
arginine are shown in Figure 3b. 
 
Figure 2. Molecular surface representaiton of MaADI. (a) An overview structure of ADI showing of the molecular surface in white 
and the Cα trace in cyan. (b) A close-up view of the substrate binding pocket of the enzyme. Enzyme-substrate polar interactions 
are denoted by dotted lines. The red arrow represents the putative entrance to the pocket. The figure was redrawn from (Das et 
al. 2004) under a free common license from Cell Press. 
 
Table 2. Important residues of PaADI. 
Residues Function or comment 
Cys406  Mounts the nucleophilic attack on the carbon atom of the guanidinium group of arginine. 
His278 Serves as a general base, activate the water molecule. Proton acceptor during the formation of a 
tetrahedral carbon intermediate. 
Glu224 One of the residues in catalytic trid, electrostaric interaction with His278. 
Asp280 Interacts with the imidazole group of His405 via the carboxylate group, which in turn interacts with Glu13. 
Invariable residue in all known ADIs. 
Asp280, Asp166 Fix the guanidinium group of the arginine substrate tightly by interactions with the carboxyl groups. 
Arg401, Arg185 Form ionic interaction with the carboxyl group of the arginine substrate. 
Phe163 Interacts with the hydrophobic part of arginine substrate. 
Glu13 His405 interacts with Glu13. It is invariant in all known ADIs. 
His405 Shares protons with Asp280 and Glu13, sometimes is replaced by an arginine, as in the case of MaADI. 
Arg165 Is fixed by electrostatic interactions with the main chain oxygen atoms of Thr408 and His-405 and with the 
hydroxyl group of Thr408. 
Arg401 Blocks the ADI active site via the side chain by forming an ion pair with the carboxyl group of Asp166 and 
occupies approximately the same position as the guanidinium group of an arginine substrate. 
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Figure 3. Crystal structural of PpADI. (a) A overview tetramer structure of PpADI, different chains are shown in distinct colors. (b) 
A zoomed view of the substrate binding pocket in subunit A: interactions between important residues and substrate arginine 
(Galkin et al. 2004) with the permission from American Society for Biochemistry and Molecular Biology.  
Recently, the third ADI structure (MpADI from Mycoplasma penetrans, PDB code 4E4J) has been 
solved by Reverter and coworkers (Gallego et al. 2012). The overall protein fold and the 
secondary structure elements found in previous ADI structures are conserved in MpADI and 
consist of the repetition of a three-stranded mixed β-sheet and α-helix forming five ββαβ 
modules in a cyclical arrangement (Figure 4). The MpADI structure displays C-alpha RMSD of 
1.54 Å and 1.85 Å towards MaADI (PDB code 1LXY) and PaADI structure (PDB code 1RXX), 
respectively (for 391 and 360 aligned residues with a pair-wise sequence identity, of 59% and 
28%). This 5-fold pseudosymmetric moiety is also characteristic of other arginine-catabolizing 
enzymes and appears to have evolved in order to interact and catalyze reactions containing 
guanidinium substrates, such as arginine. Interestingly, for the MpADI structure, this 5-fold 
pseudosymmetric α/β modular domain also contains an additional 85-residue α-helical domain 
between the first and second module (helices α 4 to α 8, see Figure 4). This five-helix bundle 
domain, that is absent in other arginine-catabolizing enzyme structures, is speculated to 
participate in the activation of processes such as apoptosis (Das et al. 2004). The active site of 
MpADI is located at the center of the structure, forming a buried and compact substrate-binding 
pocket. Similar to other ADIs that follow an induced-fit mechanism, the occurrence of ‘‘open’’ 
Chapter I: Introduction 
 Page 5 
 
and ‘‘closed’’ conformations of MpADI are necessary to permit the correct catalytic reaction, 
which in turn allows for the entry and the release of the substrate and end product, 
respectively. In the apo-structure of MpADI, corresponding to the ‘‘open’’ conformation of the 
enzyme, all the substrate binding residues for the enzymatic reaction are conserved, but need 
to undergo substantial structural rearrangements to carry out the catalytic reaction (the 
‘‘closed’’ conformation – intermediate substrate bounds MpADI) (Gallego et al. 2012).  
 
 
1.1.3. The proposed catalytic reaction mechanism of ADI 
The overall reaction catalyzed by ADI is the hydrolytic substitution of the ηNH2 group from the 
guanidinium group Cζ of L-arginine, leading to citrulline and ammonia (Figure 5). The ADI 
catalysis mechanism was proposed ADI based on the structures of PaADI and MaADI (both in 
apo- and holo-forms) (Galkin et al. 2005). Basically, the proposed mechanism comprises three 
steps: i) thiol group of Cys406 initiate a nucleophilic attack on the guanidinium group of arginine 
and a proton is transferred first to ηNH2 group; ii) water molecule is activated by His278 and 
followed by attacking the covalent intermediate to replace and release NH3; iii)the C-S covalent 
bond between enzyme and the resulting citrulline is cleaved and citrulline is released and the 
Figure 4. Ribbon representation of the MpADI 
crystal structure. The α-helix and β- strands are 
represented in red and golden, respectively, 
and are labeled sequentially from N- terminus 
(Gallego et al. 2012) under a free common 
license from PLOS Editorial and Publishing 
Policies. 
Chapter I: Introduction 
 Page 6 
 
enzyme is brought to its ground state, ready for the next catalytic cycle. Recently, two ionization 
models of ADI were further studied by using ab initio QM/MM molecular dynamics simulations: 
i) neutral state (NS) model features a protonated Cys406 and unprotonated His278, ii) ion-pair 
(IP) model envisions a deprotonated Cys406 and protonated His278 (Ke et al. 2011). The results 
indicate that the Cys nucleophile is dominated by its protonated state in the Michaelis complex, 
and the reaction barrier corresponds largely to its deprotonation. However, the relative stability 
of the two ionization states in the ADI active site has not been explicitly established in the 
simulations. Therefore, further studies are needed for more detailed elucidation of ADI’s 
catalytic reaction mechanism. 
 
 
Figure 5. A proposed mechanism of PaADI catalysis of L-arginine hydrolysis to L-citrulline. This figure was redrawn from (Galkin 
et al. 2005) with the permission from American Society for Biochemistry and Molecular Biology. 
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1.2. Anti-tumor application of ADI 
1.2.1. Amino acid depriving enzyme for anti-tumor applications 
Cancer has become the leading cause of death in the developed counties and remains one of 
the most notoriously difficult diseases to treat. One of the difficulties in combating cancer is 
that conventional chemotherapies often have unacceptable toxicities toward normal cells at the 
doses required to kill tumor cells. Therefore, novel and improved tumor specific therapeutics 
are highly sought for the cancer treatment. Amino acid depletion is such a new type of targeted 
therapy for human cancer cells that are auxotrophic for a particular amino acid by use of amino 
acids degrading enzymes such as asparaginase (Holle 1997), methioninase (Yoshioka et al. 
1998), arginase (Lam et al. 2009), arginine deiminase (Ni et al. 2008), phenylalanine 
ammonialyase (Shen et al. 1979) and tryptophanase (Yoshimoto et al. 1986). It has been studied 
for inhibition of tumor cells in vitro and in vivo inhibitory effects towards various tumors. The 
most representative anti-cancer enzyme is asparaginase, which is particularly effective in acute 
lymphoblastic leukaemia. PEG asparaginase is commercialized for acute lymphoblastic 
leukaemia treatment (Oncaspar®, pegaspargase) (Pieters et al. 2011). However, asparaginase 
treatment is sometimes accompanied by serous side-effects including anaphylactic shock, 
coagulapathies as well as liver and pancreatic toxicity (Gong et al. 2000). 
1.2.2. Arginine depriving enzyme for anti-tumor applications 
Arginine is an important amino acid that is involved in the synthesis of peptides and proteins, 
production of creatine and nitric oxide, and different metabolic pathways and cellular events. It 
is a precursor of proline, polyamines, glutamine, glutamate, and other neurotransmitters, such 
as γ-aminobutyric acid and also serves as a substrate for two important enzymes, arginase and 
nitric oxide synthetase (Morris 2002). Arginine is a non- or semi-essential amino acid in adult 
humans since many adult somatic cells can synthesize it from citrulline in two steps via urea 
cycle (as shown in Figure 6). The enzyme argininosuccinate synthetase (ASS) catalyzes the 
conversion of citrulline and aspartic acid to argininosuccinate which is then further converted to 
arginine and fumaric acid by argininosuccinate lyase (ASL). Arginine can be degraded to 
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ornithine by the urea cycle enzyme arginase. Ornithine is then converted back to citrulline by 
OTC and then recycles back to arginine from citrulline by ASS/ASL. Therefore, the ability to 
regenerate arginine from citrulline depends on the amount and activity of ASS and ASL. The 
sensitivity of cells to arginine deprivation depends on the ability of ASS and ASL to regenerate 
arginine from the alternative intermediate (ornithine, citrulline and argininosuccinate) in the 
urea cycle.  
 
Since 1930, when for the first time arginine was discovered to be essential for the growth of 
some forms of cancer, the potential of arginine degrading enzymes as therapeutic agents was 
recognized, investigated and employed for arginine auxotrophic tumor treatments. Most tumor 
cell lines die considerably more quickly during arginine deprivation than in the absence of any 
other single essential amino acids (Scott et al. 2000). Enzymes capable of depleting arginine in 
vitro include arginase existing in human liver, arginine decarboxylase from bacterial, plant and 
human, and ADI from microorganism. For example, arginine decarboxylase converts arginine to 
agmatine, which is toxic at high plasma concentration. But, arginine decarboxylase has a short 
half-life and it loses virtually all enzymatic activities upon PEGylation though PEGylation of 
arginine decarboxylase is inefficient because there are not enough lysine residues for 
Figure 6. Urea cycle in adult somatic cells. 
ASS catalyzes the conversion of citrulline 
and aspartic acid to argininosuccinate 
which is then further converted to 
arginine and fumaric acid by ASL. Arginine 
can be degraded to ornithine by arginase. 
Ornithine is then converted back to 
citrulline by OTC and then recycles back to 
arginine from citrulline by ASS/ASL. 
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polyethylene glycol to attach (Wheatley and Campbell 2002). Arginase, converting arginine to 
ornithine and urea, is limited for anti-tumor application because of its low substrate affinity (KM 
value 2-4 mM; plasma arginine 100-120 μM), short circulatory half-life (10-15 min) and sub-
optimal enzymatic activity at physiological pH (alkaline pH optimum, pH 9.3) (Tsui et al. 2009). 
Despite the disadvantages of arginase, Cheng et al. reported remission of hepatocellular 
carcinoma (HCC) induced by systemic release of endogenous hepatic arginase and proved 
PEGylated recombinant human arginase (PEG-rhArg 5,000mw) can inhibit ASS-positive HCCs 
(Cheng et al. 2005). Furthermore, ADI, another arginine-degrading microbial enzyme, has 
various biological activities including anti-proliferation, anti-angiogenesis and inhibition of 
inducible nitric oxide synthase (iNOs). ADIs have been shown to have strong in vitro and in vivo 
inhibition for arginine auxotrophic tumors (Ott et al. 2013). 
1.2.3. PEGylation of ADI 
Phoenix Pharmaceuticals, Incorporation is developing ADI-PEG-20, a PEGylated arginine 
deiminase for the potential treatment of hepatocellular carcinoma and melanoma, for which 
the Food and Drug Administration (FDA) and the European Agency for the Evaluation of 
Medicinal Products (EMEA) have granted ADI-PEG-20 orphan drug status. EMEA has granted 
ADI-PEG-20 orphan drug status for hepatocellular carcinoma treatment. PEG-ADI is also being 
investigated for the potential treatment of other types of cancers such as melanomas (Ott et al. 
2013), leukemia (Gong et al. 2000), glioblastoma (Syed et al. 2013), prostate cancer (Kim et al. 
2009) or small cell lung cancer (Kelly et al. 2012).  
1.2.3.1. Preparation and chemical characterization of ADI-PEGs 
This commercial ADI was cloned from the genomic DNA of Mycoplasma hominis, expressed in E. 
coli, isolated by differential centrifugation, refolded and then purified by anion exchange 
chromatography. The recombinant ADI comprised approximately 10% of the total bacterial 
protein (Holtsberg et al. 2002). The recombinant ADI contains 28 primary amines 
(predominantly amino group of lysine residues and N-terminal amino groups). A molar ratio of 8 
to 12 moles of 20 kDa PEG to 1 mole of ADI was chosen to maintain approximately 50% of the 
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native enzymatic activity of ADI. A succinimidyl succinate linker was used to produce ADI-PEG-
20, which was chosen for further development. PEGylation prolonged the enzymatic activity of 
ADI-PEG-20 from 1 to 7 days in mice and decreased immunogenicity by 4 to 5 log10 compared 
with native ADI (Holtsberg et al. 2002). 
1.2.3.2. Anti-tumor activity of PEG- ADI 
In vitro experiment: A panel of 16 human hepatoma and 23 melanoma cell lines and ADI-
resistant controls were treated with PEG-ADI (0.01 to 30 µg) for 7 days. IC50 values for ADI-PEG-
20 in hepatoma and melanoma cell lines ranged from 0.01 to 0.1 mg/mL and 0.01 to 0.3 mg/ml, 
respectively. ADI-resistant tumor cell lines (T47D breast adenocarcinoma, MeWo lymphoma and 
A549 lung carcinoma) survived high doses of 100 mg/mL PEG-ADI. 
In vivo experiment: Mice bearing human HCC (SK-HEP-1, SK-HEP-2 and SK-HEP-3) or melanoma 
(SK-MEL-2 and SK-MEL-28) cell line xenografts were treated with two weekly intramuscularly 
injections of ADI-PEG-20, non-PEGylated ADI or vehicle at 5 U/mouse. As results, the sizes of 
tumors in treated animals were markedly smaller than those of control mice. The survival rates 
in treated animals were more than 50% after 24 weeks, whereas no mouse survived after 7 
weeks in both saline- and non-PEGylated ADI-treated groups (Ensor et al. 2002b). 
1.2.3.3. Half-life of PEG-MhADI and duration of PEG-MhADI activity in mice 
Mice were intravenously administered 800 U/m2 of PEG-MhADI or non-PEGylated MhADI (from 
Mycoplasma hominis). The half-lives were determined by ELISA. In mice, the plasma half-life of 
PEG-MhADI was approximately 7 days, compared with approximately 4 h for non-PEGylated ADI 
(Holtsberg et al. 2002). And plasma arginine was undetectable for 6 days and returned to 
normal levels after 12 days. In mice administered non-PEGylated ADI, the plasma arginine 
concentration was lowered only by 50% and returned to the normal level by day 2 (Holtsberg et 
al. 2002). 
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1.2.3.4. Pharmacokinetics of PEG-MhADI 
Phases I and II trials were conducted in which a single intramuscular dose of ADI-PEG-20 (20, 40, 
80 and 160 U/m2) was given to 19 patients with advanced or inoperable HCC. The enzyme 
activity and concentration of ADI-PEG-20 gradually increased, peaking at day 5 for all doses, and 
remained detectable at day 15. The 160 U/m2 dose eliminated almost all plasma arginine from 
days 2 to 15. Doses of 20 and 40 U/m2 eliminated 50 and 70% plasma arginine, respectively; the 
levels of arginine returned to normal at day 15 (Ascierto et al. 2005; Izzo et al. 2004). 
1.2.3.5. Safety and efficacy 
In order to investigate the safety and efficacy of ADI for clinical application, Phase I/II, dose-
escalation study of ADI-PEG-20 (20, 40, 80 and 160 U/m2) in 19 patients with advanced or 
inoperable HCC were performed. Three cycles of either three or four weekly doses were given, 
starting the escalation from 20, 80 and 160 U/m2 as the trial progressed. The 80 and 160 U/m2 
doses depleted plasma arginine for 5 and 12 days, respectively. Complete responses, partial 
responses and disease stabilization were seen in 10.5, 36.8 and 36.8% of patients, respectively. 
The medium survival time of patients was 410 days; four patients were still alive at the time 
these data were reported (mean > 400 days; range 64 to > 680 days). Treatment was well 
tolerated with low-titer ADI antibodies not affecting efficacy (Izzo et al. 2004). 
The strategy of cancer cell starvation using amino-acid-depriving enzymes has been applied in 
several experimental and clinical anti-tumor treatments. ADI-PEG-20 is an example of anti-
tumor activity mediated by the depletion of a specific amino acid, where tumor cells are 
auxotrophic for arginine, and at present, it is in clinical trials for the therapy of HCCs and 
melanomas. Progress in ADI research raises hopes that ADI is additionally as anti-leukemic 
agent. Besides, ADI’s anti-angiogenic activity suggests that it could become effective for the 
treatment of angiogenesis-dependent diseases, such as breast cancer. Compared with 
traditional chemotherapy, ADI has several advantages including high specificity for targeting 
malignant cells and low concurred toxicity to patients. The progress in the ADI research will 
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undoubtedly facilitate the pursuit of effective treatments to combat cancers and have profound 
influence on human health. 
1.3. Directed evolution 
The past two decades have seen a significant rise in employing directed evolution for tailoring 
protein properties to meet industrial and therapeutic demands, and for broadening the 
understanding of the underlying molecular mechanisms of enzyme catalyzed chemical 
reactions. What exactly is “directed evolution”? Directed evolution (DE) is a method used in 
protein engineering that mimics the process of natural selection to evolve proteins (mainly 
enzymes) toward a desired goal. In contract to Darwin’s evolution process, the DE process in 
laboratory usually takes only few weeks or months whereas the former might takes thousands 
of years.  
The first direct and dramatic proof of directed evolution was given in the famous experiments 
by Spiegelman and coworkers on the concept of “evolution in a test tube” in 1967 (Mills et al. 
1967). Although the term had been occasionally applied for decades to describe adaptive 
evolution experiments, the first directed evolution experiment linked to an evolved enzyme was 
reported in the 1990s. In 1993, Chen and Arnold showed a successful example of tuning the 
activity of subtilisin E (a serine protease useful in several industrial applications) for unusual 
environments by sequential random mutagenesis (Chen and Arnold 1993). One year later, 
Stemmer used three cycles of DNA shuffling and two cycles of backcrossing with wild-type DNA 
to select a TEM-1 β-lactamase mutant which had a 32,000-fold increase compared to any 
published TEM-1 derived enzyme (Stemmer 1994). Until 2006 a rapid blossom of the field could 
be observed (~320 reports in 2006 Core collection; search term “Directed Evolution”) follow by 
slowdown in growth to around 450 reports since 2012 (2012: ~450; 2013: ~480; 2014: ~450). Up 
to now, DE has been used to expand and boost various enzyme properties, such as 
enantioselectivity, specificity, activity, stability and solubility. 
In broad terms, one round of directed enzyme evolution usually consists of three steps (Figure 
7): i) Diversity generation; ii) Screening for improved variants; and iii) Isolating the gene 
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encoding for the improved protein variant. Iterative cycles are usually required until the desired 
property has been changed or improved significantly. The limitation steps are the diversity 
generation of a mutant library (Schmidt-Dannert, Arnold 1999), and the development and 
validation of the screening system, which should reflect as close as possible the conditions of 
the final application. 
 
Figure 7. Steps in a traditional directed evolution experiment. It involves three key processes: i) Selection a good starting 
sequence and mutating the parent to create a library of variants; ii) Identification variants with improved function and iii) 
Isolation of gene encoding for improved variant and repeating the process until the desired function is achieved. 
1.3.1. Diversity generation  
As shown in the Figure 7, the step I (gene diversity generation) and step II (screening for 
improved variants) are the two essential and crucial steps for a successful directed evolution 
experiment. In order to generate a library with sufficient genetic diversity (step I), two processes 
namely random mutagenesis and gene recombination were established (Romero and Arnold 
2009). The most common random mutagenesis technique used for introduction of point 
mutations is error-prone polymerase chain reaction (epPCR) under low fidelity conditions-with 
the addition of manganese ions (Mn2+) (Drummond et al. 2005). Taq DNA polymerase from 
Thermus aquaticus that lacks a 3’-5’ proofreading exonuclease activity, is used in the most cases 
of generate libraries by epPCR (Fujii et al. 2006). By increasing or decreasing the concentration 
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of manganese chloride, the error frequency in the target gene could be tuned to different 
active/inactive ratios of a mutant library. Beside this, there are many other methods for 
changing the error rates of the polymerase, such as by adding unbalanced nucleotide 
concentrations, employing nucleotide analogs, increased number of PCR cycles, and so on 
(Wong et al. 2007).  
The recombination techniques offer a major advantage over random mutagenesis because it 
can accumulate beneficial mutations and remove deleterious ones and is useful for a later stage 
of directed evolution experiments. Many methods for DNA recombination have been developed 
and applied in protein engineering campaigns such as DNA shuffling (Stemmer 1994), staggered 
extension process (StEP) (Zhao et al. 1998), random chimeragenesis on transient templates 
(RACHITT)  (Coco et al. 2001) and phosphorothioate-based DNA recombination method (PTRec) 
(Marienhagen et al. 2012).  
Despite epPCR-based methods are simple and effective, their disadvantages are obvious: i) high 
number of transitions but low transversion mutations, ii) lack of consecutive nucleotide 
exchange, and iii) a high probability of stop codons and disruptive amino acids like Gly and Pro 
(Wong et al. 2004). Recently, many researchers are moving beyond traditional directed 
evolution, developing new methods for designing smaller or higher quality libraries (Ruff et al. 
2013) (such as dITP-PCR(Pai et al. 2012), TRINS (Kipnis et al. 2012) and SeSaM (Mundhada et al. 
2011)). For example, the Sequence Saturation Mutagenesis (SeSaM) diversity generation 
method was developed for overcoming these limitations stemming from polymerase bias. The 
SeSaM techniques for the diversity generation of a mutant library has many advantages, such as 
an unbiased mutational spectrum, a controllable mutation frequency, and enable to generate 
consecutive nucleotide substitutions or codon-based substitutions (Wong et al. 2006). 
Computational tools can also assist the directed evolution by in silico analysis to estimate the 
generated diversity (e.g. MAP (Verma et al. 2012b) and PEDAL-AA (Firth and Patrick 2008)), to 
select an appropriate randomization scheme for library construction (Codon Calculator (Firth 
and Patrick 2008) and AA-Calculator (Firth and Patrick 2008)), and to design saturation 
mutagenesis experiment (TopLib (Nov 2012)). The computer-aided protein directed evolution 
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(CAPDE) reviewed by Roccatano et al. offers the possibility to generate libraries with high 
frequency of active and improved variants (Verma et al. 2012a).  
1.3.2. Screening systems 
The second crucial step for a successful directed evolution is the development of a reliable 
screening system, which allows identifying improved variants from a large pool of mutants. Solid 
phase and microtiter plate based screening are still routinely and widely used in directed 
evolution, despite of the increasing number of novel screening methods available, such as in 
vitro compartmentalization (Fallah-Araghi et al. 2012) and liposome display (Fujii et al. 2013).  
Solid phase, mainly agar plate screening (screen and selection throughput: 105-106), is usually 
based on color change, so that the activity difference could be simply distinguishable by 
observation. However, it lacks accuracy and therefore it more often be used as a pre-screening 
method (Martinez and Schwaneberg 2013). In contrast, microtiter plate assays can be used to 
screen for up to 104 clones and are suitable for quantitative measurement, although practically 
this number of clones is seldom reached. The most common platform for screening random 
mutagenesis libraries is in microtiter plates. Microtiter plate based screenings enable the use of 
various analytical tools and offer a great dynamic range, but the screening capacity is usually 
limited to less than 104 variants per day and therefore these can be classified as medium 
throughput systems. To overcome the throughput limitation, the development of encapsulation 
technologies, microfluidics or flow cytometry based methods became attractive alternative high 
throughput screening systems (Tu et al. 2011). These techniques allow to test up to 107 variant 
per hour. However, the main challenge in this approach is to find suitable fluorogenic chemicals 
(as substrates for target proteins) that do not cross the oil-phase barrier of the droplets 
(Dietrich et al. 2010). Recently, product-driven, transcription factor-based biosensors have been 
integrated in flow cytometry based screening systems for genomic screening (Binder et al. 
2012), enzyme evolution (Schendzielorz et al. 2014) and isolation of catabolic genes from 
metagenome libraries (Uchiyama et al. 2005). The employed transcription factors are regulated 
by product formation or accumulation within the host organism which in turn triggers the 
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expression of a fluorescent protein (Schallmey et al. 2014). The generated fluorescence signal 
correlates to product formation within millimolar (mM) concentrations. 
Furthermore, many efforts have been made to push the boundaries of evolution schemes, 
attempting new selection systems with improved features, and faster selection procedures. A 
comparison of available screening methods for a directed evolution experiment is summarized 
in the following Table 3. 
Table 3 Comparison of screening and selection technologies. 
Strategy Library size Advantage Limitation 
Selection ∼109 Yields desirable variants Only possible if activity gives growth 
advantage 
Agar plate screen ∼105 Simple to operate Limited dynamic range 
Microtiter plate screen ∼104 All analytical methods possible, 
excellent dynamic range 
Relatively low screening capacity 
Cell-in-droplet screen ∼109 Large libraries Fluorescence detection and DNA 
modifying enzymes 
Cell as microreactor ∼109 Large libraries Fluorescence detection 
Cell surface display/Liposome 
display/Megavalent bead 
display 
∼109 Large libraries Fluorescence detection 
In vitro compartmentalization 
(IVC) 
∼1010 No cloning steps, large libraries Fluorescence detection and DNA 
modifying enzymes 
Phage assisted continuous 
evolution (PACE) 
- It enables the 
sustained evolution of protein 
variants through hundreds 
of rounds of evolution in a 
week 
Only be used to evolve proteins or 
activities that 
directly or indirectly involve 
expression 
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1.4. Objectives 
The main objectives of this PhD project were: i) Development of a sensitive assay (μM range) in 
microtiter plate (MTP) format for obtaining improved PpADI variants with high activity under 
physiological conditions (pH, ion concentrations and arginine concentration); ii) To develop a 
flow cytometry based screening system to reengineer ADIs by directed evolution for in vivo 
applications (µM) for high throughput screening of PpADI variants. iii) To generate and screen  
random mutagenesis libraries and focused mutagenesis libraries based on the developed assays 
and to improve PpADI activity under physiological conditions; iv) To modify PpADI’s surface for 
improving the PEGylation efficiency and avoid dramatic loss of PpADI activity; v) To study 
structure-function relationships by molecular modeling and molecular dynamic simulation on 
the improved variants; vi) Tumor cell line test of improved PpADI variants to investigate their  
inhibitory effect towards arginine-auxotrophic tumors. 
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2. Chapter II: Directed PpADI evolution for obtaining improved PpADI variants 
with high activity under physiological conditions using a sensitive screening 
system in MTP format 
2.1. Declaration 
Parts of this chapter have been published in the journal “Applied Microbiology and 
Biotechnology”. The usage of that paper is allowed from Copyright Clearance Center under 
license # 3556410030872. 
2.2. Introduction 
Current research efforts of ADI are focused on ADI’s in vivo inhibitory effects towards tumors, 
clinical trials for HCCs (Glazer et al. 2010), melanomas (Ott et al. 2013), leukemia (Gong et al. 
2000), glioblastoma (Syed et al. 2013), prostate cancer (Kim et al. 2009), small cell lung cancer 
(Kelly et al. 2012), and inhibitory mechanisms of ADI to tumors (Kim et al. 2009). Despite of the 
progress, ADIs’ application in cancer treatment is limited by their catalytic performance under 
physiological conditions (e.g., pH (7.35-7.45) and arginine concentration of 100-120 μM)) (Zhu 
et al. 2010b). For instance, a reduction of MhADI’s (ADI from Mycoplasma hominis) KM value 
from240 to 100 μM would, in terms of Michaelis-Menten kinetics, result in a ~2-fold velocity 
increase at 100 μM arginine. ADI from Pseudomonas plecoglossicida (PpADI), one of the most 
well studied ADIs, holds an excellent potential as an anticancer drug against arginine-
auxotrophic tumors. In previous directed evolution campaigns on PpADI, the kcat value was 
improved significantly from 0.18 s−1 (WT) to 11.64 s−1 (M6), and S0.5 value decreased thereby 
from 1.30 mM (WT) to 0.81 mM (M6) (Zhu 2010; Zhu et al. 2010b). The variant M2 displayed a 
pH shift from 6.5 to 7.0, which proved for the first time that an ADI can be engineered for 
efficient catalysis at physiological pH (Zhu et al. 2010a). In order to efficiently starve tumor cells 
through arginine depletion (100-120 µM), it is crucial to further decrease the S0.5 value of PpADI 
under physiological conditions. To achieve the latter objective, a sensitive detection/screening 
system is indispensable. The commonly used screening system based on colorimetric citrulline 
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detection via diacetyl monoxime/thiosemicarbazide (DAM/TSC) assay in microtiter plate (MTP) 
format has a reliable detection range from 0.3 mM to 6.0 mM (Archibald 1944; Zhu et al. 
2010b). In order to screen for ADI variants which operate efficiently at 100 µM arginine 
concentration (physiological conditions), a more sensitive screening system was required to 
detect ADI activity at physiological arginine concentrations. Therefore, a coupled screening 
system in MTP format was developed in this part, which allows a continuous and linear 
detection of ammonia between 5 and 300 μM. The screening system, employing a continuous 
ammonia detection assay, was validated in two directed evolution campaigns yielding PpADI 
variants with significantly lowered S0.5 value and IC50 value for two melanomas cell lines. 
2.3. Materials and Methods 
All chemicals were of analytical-reagent grade or higher quality and were purchased from 
Sigma-Aldrich, and Applichem (Darmstadt, Germany); and all other enzymes were purchased 
from New England Biolabs, Fermentas, unless stated otherwise. Thermal cycler (Mastercyler 
gradient; Eppendorf, Hamburg, Germany) and thin-wall PCR tubes (Multi-ultratubes; 0.2 mL; 
Carl Roth, Germany) were used in all PCRs. All kinds of Microtiterplates (flatbottom transparent 
MTP, black transparent MTP and v-bottom transparent MTP) were purchased from Greiner Bio-
One GmbH (Frickenhausen, Germany). The amount of DNA in cloning experiments was 
quantified by using a Nano-Drop photometer (NanoDrop Technologies, Germany). For 
purification, the resins of super-Q anion-exchange were purchased from TOSOH (Stuttgart, 
Germany), while the PD-10 desalting columns were purchased from GE Healthcare (Darmstadt, 
Germany). GDH was purchased from Sigma-Aldrich (No. G2626).  
2.3.1. Development of an ammonia detection based screening assay in 96-well plate format 
In order to scale-down ammonia detection assay in 96-well microtiter plate for high-throughput 
screening under micromole scale arginine, an assay was developed which is based on the 
amount of the released ammonia from the substrate as a result of the activity of PpADI. This 
reaction was coupled with a subsequent dehydrogenation step catalyzed by GDH enzymatic, 
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and a continuous monitoring of the absorbance decreased velocities of NADH was performed at 
physiological conditions (37 °C, pH 7.4). For optimization, different concentrations of NADH (0.2 
mM, 0.4 mM, 0.6 mM, 0.8 mM and 1.0 mM) were tested at physiological conditions (PBS buffer, 
37 °C, pH 7.4). The concentration of the auxiliary substrate, α-ketoglutarate, was selected as 
5mM, which was sufficient to catalyze the dehydrogenation reaction under optimized 
conditions (0.4 mM NADH with 5.55 U GDH) and at this concentration of α-ketoglutarate no 
effect can be observed on the initial velocity of the hydrolysis reaction catalyzed by arginine 
deiminase (Figure 8) (Weickmann and Fahrney 1977). Initial velocities were calculated from the 
slope at 340 nm (v∆A) in flat-bottom MTP. Equation (1) based on Beer-Lambert law was used for 
calculating the ammonia production velocity (v∆c), and further obtaining the activity of PpADI. 
Absorption coefficient (ε) of NADH is 6200 M-1 cm-1. Liquid height (b) in each well of MTP was 
approximately 0.59 cm (total volume of reaction mixture in each well of MTP is 200 µl). 
 v∆A =  ε ×  b × v∆c                            (1) 
After the optimization of NADH and GDH amounts, the decreased velocities of NADH consumed 
by GDH at different concentrations of NH4
+ (5 µM, 10 µM, 15 µM, 20 µM, 40 µM, 80 µM, 100 
µM, 200 µM, 300 µM) were measured. Additionally, the activity of PpADI WT and parent M6 
were measured using ammonia detection assay to compare with the citrulline colorimetric 
assay for consistency (Zhu et al. 2010b). 
Coefficient measurements were carried out in MTP format using culture from E.coli BL21-Gold 
(DE3) lacking PpADI (negative control) and in a separate experiment containing PpADI M6. The 
apparent coefficient of variation (Coefficientapp) was based on the decreased velocity of 
absorbance at 0.4 mM NADH values obtained from the MTP with PpADI M6. The true coefficient 
of variation (Coefficienttrue) was calculated by subtracting the background absorbance value of 
the MTP with negative control from the value of PpADI M6. 
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2.3.2. Generation of epPCR (error-prone PCR) library 
Three error-prone PCR (epPCR) libraries (with 0.05 mM, 0.08 mM, 0.10 mM Mn2+) were 
generated using standard conditions (see supplementary materials Tables 4–6), and the 
improved variant M6 (WT+K5T/D38H/D44E/A128T/E296K/H404R) was used as a template. The 
purified epPCR products were cloned into pET42b(+) vector by MEGAWHOP (Table 7) as 
described (Miyazaki and Takenouchi 2002). The DpnI digested MEGAWHOP product was 
transformed into E.coli BL21-Gold (DE3) for expression and screening (Miyazaki and Takenouchi 
2002). 
Table 4. Compositions for the different PCR reactions 
Components Template 
[ng/μL] 
Primer 
[μM] 
Megaprimer
a
 
[ng/μL] 
dNTP 
[mM] 
MnCl2 
[mM] 
Polymerase 
[U] 
epPCR 0.8 0.5 - 0.2 0.08 2.5
b
 
MEGAWHOP 1 - 10 0.2 - 2.5
c
 
PLICing insert 0.8 1 - 0.2 - 2.5
b
 
PLICing vector 0.8 1 - 0.2 - 2.5
c
 
Two step SDM PCR 1 1 - 0.2 - 2.5
c
 
a
 Amplified PpADI by epPCR; 
b 
Taq Polymerase; 
c 
PfuS Polymerase 
 
Table 5. Error prone PCR (epPCR) program. 
Step  Temperature [°C] Time [sec] Cycle [-] 
Initial denaturation  95 120 1x 
Denaturation  95 30  
Annealing  55 30 25x 
Elongation  72 120  
Final elongation  72 600 1x 
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Table 6. Primers for epPCR. 
Name Sequences (5’-3’) 
epPCR_PpADI_fwd TAC ATA TGT CCG CTG AAA CAC AGA AG 
epPCR_PpADI_rev GTG CTC GAG TTA GTA GTT GAT CGG 
 
Table 7. MEGAWHOP PCR program. 
Step  Temperature [°C] Time [sec] Cycle [-] 
Exonuclease activity  72 300 1x 
Initial denaturation  98 120 1x 
Denaturation  98 30  
Annealing 60 30 25x 
Elongation 72 240  
Final elongation  72 600 1x 
 
 
2.3.3. Generation of a PpADI SeSaM (Sequence Saturation Mutagenesis) library 
The Sequence Saturation Mutagenesis (SeSaM) library was generated using an equimolar 
mixture of the two improved variants PpADI M13 and PpADI M14 identified from the epPCR 
library (Mundhada et al. 2011). The generation of the SeSaM library was carried out according to 
the handbook (SeSaM-Tv-II classic version 0.21; SeSaM-Biotech GmbH, Aachen, Germany) 
(Mundhada et al. 2011). In general there are 4 steps in the current SeSaM protocol: Step 1 - A 
PCR to incorporate phosphorothioate nucleotides into the gene of interest followed by cleavage 
of the phosphorothioate bonds to create evenly distributed fragments of the gene; Step 2 - 
Elongation of fragments in Step 1 with universal bases at 3’-OH terminal; Step 3 - Fragments 
with the universal bases are elongated to their full length using the full length gene template; 
Step 4 - Mutations are generated in a final PCR to create mutant libraries that are ready for 
cloning. The SeSaM products were ligated to pET42b(+) vector by PLICing (Blanusa et al. 2010). 
PCR protocols (Tables 8 and 9) and the primers (Table 10) used for PLICing are described in SI. 
The presence and size of the amplified genes and vectors were confirmed by electrophoresis 
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using 0.8% TAE-gel. The resulting DNA constructs were subsequently transformed into 
chemically competent E. coli BL21-Gold (DE3) cells following a standard PLICing protocol 
(Blanusa et al. 2010). 
Table 8. PLICing program for insert. 
Step  Temperature [°C] Time [sec] Cycle [-] 
Initial denaturation  96 120 1x 
Denaturation  96 30  
Annealing 60 30 25x 
Elongation 68 120  
Final elongation  68 600 1x 
 
 
Table 9. PLICing program for vector. 
Step  Temperature [°C] Time [sec] Cycle [-] 
Initial denaturation  96 120 1x 
Denaturation  96 30  
Annealing 60 30 25x 
Elongation 68 240  
Final elongation  68 600 1x 
 
 
Table 10. List of primers used for PLICing and cloning of ADI. Asterisks mark the locations of phosphorothioate bonds. 
Primer name Sequence 5’-3’ 
PpADI_fwd g*a*c*t*c*a*c*t*a*t*a*g*GGGAATTGTGAGCGG 
PpADI_Rev g*c*a*a*a*a*a*a*c*c*c*c*TCAAGACCCGTTTAGAG 
Vector_fwd c*t*a*t*a*g*t*g*a*g*t*c*GTATTAATTTCGCGGGATC 
Vector_rev g*g*g*g*t*t*t*t*t*t*g*c*TGAAAGGAGGAAC 
 
2.3.4. Cultivation and expression of PpADI in 96-well MTP 
Colonies grown on LBkan agar plates were transferred, by using toothpicks, into 96-well 
microtiter plates, containing LSG noninducing medium (150 mL) (Studier 2005) supplemented 
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with kanamycin (50 µg mL-1). After 16 h of cultivation in a microtiter plate shaker (Multitron II, 
Infors GmbH, Einsbach, Germany; 37 °C, 900 rpm, 70% humidity), each well was replicated by 
using a replicator (EnzyScreen BV, Leiden, Netherlands) into a second series of 96-well MTP 
containing autoinduction medium LS-5052 (150 mL) supplemented with kanamycin. The first set 
of plates was stored at -80 °C after addition of glycerol. The clones in the second set of plates 
were cultivated for 12 h (Multitron II, Infors GmbH, 37 °C, 900 rpm) and used for screening.  
2.3.5. Screening procedures 
2.3.5.1. Ammonia detection based screening assay in MTP format 
A modified protocol for ammonia detection (as described in 2.3.1) was used for PpADI mutant 
library screening at physiological conditions to identify improved variants. 
The expression and reaction conditions were optimized (optimal setup: 150 µL optimized LS5052 
auto-induction medium). Cells were lysed by adding 80 µL lysozyme (final concentration: 80 
µg/mL) into each well containing frozen cell pellet. The cell pellet was resuspended by pipetting 
and incubated at 37 °C for 20 minutes. After centrifugation at 4000 rpm for 15 minutes, the 
supernatant (20 µL from each well) was transferred into fresh plates for assay purposes. The 
assay plates were supplemented with 0.4 mM NADH, 5 mM α-ketoglutarate, and 5.55 U GDH 
into each well, and the assay plates were incubated at 37 °C for 10 minutes. The cascade 
reaction was initiated by the addition of arginine solution (80 µL in each well) and absorbance at 
340 nm was recorded immediately by using a microtiter plate reader (Tecan Infinite M2000 Pro, 
Tecan Group AG, Zürich, Switzerland). 
2.3.5.2. Site-directed mutagenesis of the PpADI M6 at selected positions 
Site-directed mutagenesis of the PpADI M6 at amino acid positions 30, 37, 129, 148, and 291 
was performed as previously described (Zhu et al. 2010b). Recombined mutants M17 
(M14+L148P), M18 (M15+G129S), and M20 (M16+L148P) were generated using M14, M15 and 
M16 as starting variants and by combining beneficial substitutions, respectively. Variants M19 
Chapter II: Directed PpADI evolution for obtaining improved PpADI 
variants with high activity under physiological conditions using a 
sensitive screening system in MTP format 
 Page 25 
 
(M17+V291L) and M21 (M20+V291L) were subsequently generated based on M17 and M20, 
respectively. The PCR protocol and primers used for mutagenesis are described in Table 11 and 
Table 12. The resulting PCR product was purified by using a PCR purification kit (Macherey-
Nagel, Düren, Germany), then digested with DpnI and transformed into E. coli BL21-Gold (DE3) 
(Zhu et al. 2010a). 
Table 11. Two-step PCR program for site-saturation and site-directed mutagenesis. 
Step 1 Temperature [°C] Time [sec] Cycle [-] 
Initial denaturation  98 120 1x 
Denaturation  98 30  
Annealing 55 45 3x 
Elongation 72 240  
 
Step 2 Temperature [°C] Time [sec] Cycle [-] 
Denaturation  98 30  
Annealing 55 45 15x 
Elongation 72 240  
Final elongation  72 600 1x 
 
Table 12. Primers for site-directed mutagenesis library. Substituted nucleotides are underlined. 
Name Sequences (5’-3’) 
K30R_fwd CCGGGACTGGCGCACAGGCGCCTGACCCCGAGC 
K30R_rev GCTCGGGGTCAGGCGCCTGTGCGCCAGTCCCGG 
C37R_fwd CTGACCCCGAGCAACCGCCACGAGCTGCTGTTC 
C37R_rev GAACAGCAGCTCGTGGCGGTTGCTCGGGGTCAG 
G129S_fwd ATCGGCGGCGTGACGTCCCAGGACCTGCCGGAG 
G129S_rev CTCCGGCAGGTCCTGGGACGTCACGCCGCCGAT 
V291L_fwd CGCGACCTGCTCACGGTTTTCCCGAAAGTGGTG 
V291L_rev CGGGAAAACCGTGAGCAGGTCGCGGTCGCAGAAG 
L148P_fwd GTACAACGACTACCCGGGCCACTCCAGCTTC 
L148P_rev GAAGCTGGAGTGGCCCGGGTAGTCGTTGTAC 
Chapter II: Directed PpADI evolution for obtaining improved PpADI 
variants with high activity under physiological conditions using a 
sensitive screening system in MTP format 
 Page 26 
 
2.3.6. Expression, purification, and quantification of PpADI WT, parent M6 and variants M19 
and M21 
The PpADI WT, the parent (PpADI M6), and the two ‘best’ variants M19 and M21 were 
expressed in shaking flask cultures and purified by anion-exchange chromatography and PD-10 
desalting columns. A thermo scientific pierce BCA protein assay kit (Rockford, IL, USA) was used 
to quantify the purified proteins. 
2.3.7. Determination of kinetic constants of PpADI WT, parent M6 and variants M19 and M21 
The kcat and ‘KM’ (S0.5) values were determined from initial velocity data measured as a function 
of substrate concentration. Enzyme reaction was carried out at 37 °C by following the same 
procedure as described above for MTP format library screening using the purified enzyme (20 
µL) and the substrate solution (80 µL, 0.1 mM to 10 mM of arginine in PBS buffer, pH 7.4). The 
obtained initial velocity data were fitted to the Hill equation (2) of allosteric sigmoidal model of 
by using GraphPad Prism 6 (GraphPad Software, Inc., San Diego, CA) as previously described 
(Gesztelyi et al. 2012; Zhu et al. 2010a). The kcat was calculated from the ratio of Vmax and 
enzyme concentrations. The enantioselectivity of PpADIs towards the conversion of 1 mM (D, L)-
arginine was determined under the same conditions (as mentioned above) after 10 min reaction 
time by using L-arginine, D-arginine, and (D, L)-arginine as substrates, individually. L- or D-
citrulline were detected by citrulline detection assay (Archibald 1944). The enantiomeric excess 
(e.e.) was calculated by the concentrations of two enantiomers (L- and D- citrulline) according to 
the equation (3). 
 
 
0.5
max
h
hh
v S
v
S S



                                                                      (2) 
𝑒. 𝑒. % =
[𝐿−citrulline]−[𝐷−citrulline]
[𝐿−citrulline]+[𝐷−citrulline]
∗ 100%                     (3) 
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2.3.8. Homology modeling  
A homology model of the PpADI M6 (based on the crystal structure of PaADI, PDB code: 2A9G) 
was successfully constructed as previously reported (Zhu et al. 2010a). All the homology models 
of PpADI variants (PpADI M6+C37R, PpADI M13 and PpADI M19) were built using “BuildModel” 
tool implemented in FoldX software with the model of M6 as a template (Schymkowitz et al. 
2005). 
2.3.9. Cultivation conditions for melanoma cell line cultures 
Two melanoma cell lines, SK-MEL-28 and G361 (kind gifts from Prof. Dr. med. Jens Malte Baron, 
Uniklinik RWTH Aachen), were cultivated at 37 °C, 5% CO2 in DMEM medium (Life Technologies, 
Darmstadt, Germany) supplemented with 10% fetal calf serum (FCS) (Hyclone), non-essential 
amino acids (1×) (Life Technologies, Darmstadt, Germany), pyruvate(1×) (Life Technologies, 
Darmstadt, Germany), 100 µg/mL streptomycin, and 100 µg/mL penicillin. 
2.3.10. Cell proliferation assay 
Quantitative cell proliferation assays were performed using the Cell Titer-Blue dye (Promega, 
Mannheim, Germany) according to the instructions provided by the manufacturer. Cells 
(2.5×103) in a volume of 180 µL of growth medium were added to each well of MTP. Purified 
PpADI enzymes (0.1-10 µg/mL, PpADI WT, M6, and M19) were sterilized by filtration through 0.2 
µM filters (Carl Roth, Karlsruhe, Germany). 20 µL of the sterile enzymes were added into the 
growth medium after cells were grown for 24 h. The plates were incubated for 6 days at 37°C in 
an incubator containing an atmosphere of 95% air and 5% CO2. 20 µL of Cell Titer-Blue dye was 
added to each well. The plates were incubated for an additional 3 h after the addition of 20 µL 
of Cell Titer-Blue dye to each well. The fluorescence at 560Ex/590Em was then measured using an 
MTP reader (Tecan Group AG, Zürich, Switzerland) in flat-bottomed black MTP (Greiner Bio-One 
GmbH, Frickenhausen, Germany). The concentration of PpADI enzymes required for 50% 
inhibition of the cells in culture was defined as the IC50, and IC50 values were determined by 
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using GraphPad Prism 6 (GraphPad Software, Inc., San Diego, CA). All values are expressed as 
mean±SD. 
2.4. Results 
The result section is mainly divided into three parts. In section 2.4.1, a more sensitive screening 
system based on ammonia detection in 96-well microtiter plate to reliably detect ≥0.005 mM 
ammonia was developed. Subsequently, in section 2.4.2, after screening ~5,500 clones with the 
ammonia detection system (ADS) in two rounds of random mutagenesis and site-directed 
mutagenesis, variant M19 with increased kcat value (21.1 s
-1; 105.5-fold higher compared to WT) 
and reduced S0.5 value (0.35 mM compared to 0.81 mM (M6) and 1.30 mM (WT)) was identified. 
Further Improved performance of M19 was validated by determining IC50 values for two 
melanoma cell lines in section 2.4.5. The IC50 value for SK-MEL-28 dropped from 8.67 µg/mL 
(WT) to 0.10 µg/mL (M6) to 0.04 µg/mL (M19); the IC50 values for G361 dropped from 4.85 
µg/mL (WT) to 0.12 µg/mL (M6) to 0.05 µg/mL (M19). 
The starting point (parent) of the directed evolution campaign was PpADI M6 
(WT+K5T/D38H/D44E/A128T/E296K/H404R), a variant generated from the wild-type PpADI 
(PpADI WT) (GenBank: EU030267). (Zhu 2010; Zhu et al. 2010a; Zhu et al. 2010b) 
2.4.1. Development of ammonia detection system (ADS) for PpADI activity detection and 
library screening 
The detection principle of the continuous ammonia detection system (ADS) is shown in the 
Figure 8. ADS employs an enzymatic cascade reaction (ADI and L-glutamic dehydrogenase from 
bovine liver (KM < 0.1 mM)) leading to accumulation of NAD
+. The amount of NADH consumed 
during the dehydrogenation step is directly proportionate to the ammonia produced by PpADI 
and is used as measure of enzymatic activity. In comparison, Figure 8 also shows the citrulline 
detection system used previously in directed PpADI evolution for increased activity (Weickmann 
and Fahrney 1977; Zhu et al. 2010a). 
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Figure 8: Arginine conversion by ADI and the principle of citrulline detection system (by using the DAM/TSC assay) and ammonia 
detection (by NAD
+
/NADH coupled enzymatic reactions) system. 
ADS was optimized in terms of reaction parameters (e.g. concentrations of NADH, α-
ketoglutarate, and GDH; data not shown) to maximize NADH consumption at low ammonia 
concentrations and enable screening of PpADI mutant libraries in 96-well MTP format. Under 
optimized conditions, the velocity of NADH consumption in the control experiments (empty 
vector) was negligible (< 1.0×10-5 s-1 at 340 nm), and its linear detection ranges from 5 µM to 
300 µM ammonium (Figure 9) with a correlation coefficient (R2) higher than 0.99 (Figure 9). A 
true coefficient of variation of 12.6% was obtained for parent PpADI M6 (see Figure 10). 
Screening systems with a true coefficient of variation of <15% were routinely employed in 
successful directed evolution campaigns (Despotovic et al. 2012). At a concentration of 1 mM 
arginine, the citrulline and ammonia detection system yielded comparable activity values for 
PpADI WT and variant M6 (Table 13).  
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Figure 9. Performance criteria of the continuous ammonia detection system (a) Time courses of ammonia detection assay with 
varied concentrations of ammonia; (b) Standard curve of ammonia detection system. v∆A340 (calculated from Figure 9a) 
represents the decrease rate of NADH (A340); (c) Calibration curve of the citrulline detection assay when citrulline concentrations 
are below 300 μM. 
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Figure 10. The absorbance decreased velocities of NADH in a 96-well plate loaded with PpADI variant M6 in descending order of 
arginine conversion, which was quantified with the ammonia detection system. The apparent coefficient of variation was 
calculated without subtracting the background, while the true coefficient of variation was obtained after background 
subtraction. 
Table 13. Activity comparison of PpADI M6 to PpADI WT (crude cell extract from culture in flask) using ammonia detection assay 
(v∆c,app) and citrulline detection assay
 
(A490).  
 v∆c,app (μM·s
-1
) Ratio (PpADI WT/PpADI M6) A490 
Ratio of A490 (PpADI WT)/  
A490 (PpADI M6) 
PpADI WT 0.057 - 0.048 - 
PpADI M6 0.842 14.7 0.704 14.6  
* 1 mM arginine was used as substrate. 
 
2.4.2. Validation of the continuous ammonia detection system (ADS) for directed ADI 
evolution by screening an epPCR library and a SeSaM library  
Figure 11 outlines the directed PpADI evolution strategy employing the ADS screening system. 
M6, identified in previous directed PpADI evolution experiments (Zhu et al. 2010a), was used as 
the starting variant due to its increased kcat value (11.64 s
-1) and slightly decreased S0.5 value (0. 
81 mM). M6 was subjected to two rounds of random mutagenesis which employed epPCR 
(Mn2+ = 0.08 mM; first library) (Ruff et al. 2013) and SeSaM-Tv-II (second library) (Mundhada et 
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al. 2011), followed by an MTP-based screening and rescreening (of hits) employing ADS. The 
improved variants were sequenced and the beneficial substitutions were identified.  
 
Figure 11. The procedure of directed ADI evolution in 96-well microtiter plate (MTP) format: (1) mutant library generation by 
epPCR or SeSaM, (2) transformation of mutant library into E. coli BL21 (DE3), (3) preparation of master plate, (4) preparation of 
expression plate, (5) screening of PpADI mutant library in 96-well MTP employing the continuous ammonia detection system 
and rescreening of improved variants in pentad, and (6) identification and characterization of improved variants. 
 
Figure 12. The products of epPCR (a) and Megawhop (b). Lane 1, 2 3 (in Figure 12a) are showing the PCR products by using 0.05 
mM, 0.08 mM and 0.10 mM Mn
2+
 for the epPCR libraries generation, respectively. 
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Three epPCR libraries with 0.05 mM, 0.08 mM, 0.1 mM Mn2+ were generated using the 
improved variant M6 as template (Figure 12). As a result, 0.08 mM MnCl2, which generated 48% 
inactive mutants, was thereby selected for library generation, while the inactive ratios of 0.05 
mM and 0.1mM were 36% and 62%, respectively. The reason is that epPCR mutant libraries 
with a ratio of 50% active and 50% inactive clones have often been used successfully in directed 
evolution experiments, improving enzyme properties (Martinez et al. 2013). For epPCR library 
screening, an arginine (PBS buffer, pH 7.4) concentration of 0.4 mM was used. After screening 
around 2,500 clones, 120 variants showed 2-3 fold higher activity than the parent M6, and 23 
mutants showed 3-4 fold higher activity compared to M6. The expression levels of the improved 
variants were analyzed by SDS-PAGE, and a total of 39 variants were selected from the epPCR 
library for rescreening. Two concentrations of arginine, 0.3 mM and 0.4 mM, were used during 
rescreening. Crude cell extracts of variants M13 and M14 displayed the highest activities among 
all the improved variants and showed a 2.5-fold and a 3.1-fold higher activity than parent M6 at 
0.3 mM arginine, respectively. Therefore, variants M13 and M14 were chosen for preliminary 
kinetic investigations using crude cell extracts. The S0.5 values of M13 (0.45 mM) and M14 (0.53 
mM) were significantly lower than that of the parent M6 (0.81 mM). Sequencing results (Table 
14) revealed that M14 has two additional substitutions (K30R and C37R), and M13 contains a 
single substitution L148P. 
An equimolar mix of the plasmids of M13 and M14 was used as the template for generating a 
SeSaM library. The SeSaM-Tv-II mutant library yielded about 63% active variants. After 
screening of ~3,000 clones using decreased arginine concentration (0.3 mM) compared to the 
epPCR library as substrate, around 50 clones showed up to relative 1.5-fold increase in activity 
at 0.3 mM arginine compared to parent M14. 0.2 mM and 0.3 mM arginine were used for 
rescreening which resulted in the identification of two mutants, M15 and M16. The activity of 
M15 was about 2-fold higher than M6 (crude cell extracts). M16 showed a 1.4-fold increase in 
activity at 0.2 mM arginine when compared to M14, and 3.1-fold increase in activity relative to 
M6 (in crude cell extracts). Apparent S0.5 values of M15 and M16 are 0.46 mM and 0.51 mM, 
respectively (Table 14), which suggest that these two variants exhibit substantially increased 
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affinity towards arginine. Sequencing results showed that both variants (M15 and M16) 
harbored K30R and C37R substitutions, which were also found in M14. The substitution G129S 
(GGC→TCC, in M15) and V291L (GTC→CTC, in M16) were resulted from transversion at the 
nucleotide level. An enriched mutational bias towards transversions and consecutive nucleotide 
exchange (GGC→TCC, in M15) are characteristics of the SeSaM method (Mundhada et al. 2011). 
Table 14. Overview of newly identified nucleotide changes and amino acid substitutions    
Variants Amino acid substitutions (nucleotide changes) Mutagenesis methods 
M13 L148P (CTG→CCG) epPCR 
M14 K30R (AAG→AGG); C37R (TGC→CGC) epPCR 
M15 V291L (GTC→CTC); K30R; C37R SeSaM 
M16 G129S (GGC→TCC); K30R; C37R SeSaM 
M17 K30R; C37R; L148P SDM 
M18 K30R; C37R; G129S; V291L SDM 
M19 K30R; C37R; L148P; V291L SDM 
M20 K30R; C37R; G129S; L148P  SDM 
M21 K30R; C37R; G129S; L148P; V291L SDM 
 
2.4.3. Recombination of beneficial mutations by site-directed mutagenesis (SDM) 
Next, five substitutions (K30R, C37R, L148P, G129S, V291L; see above) identified from random 
mutagenesis libraries were individually introduced to M6 in order to assess the contribution of 
each substitution in lowering S0.5 value and increasing kcat value. Two substitutions (C37R and 
L148P) reduced the S0.5 value. Two variants exhibited decreased S0.5,app values (M6+C37R: 0.49 
mM, M6+L148P: 0.45 mM) compared to M6 (0.81 mM; Table 15). In addition to the apparent 
S0.5 value, the activity of PpADI at physiological arginine concentration (~100 µM) is another key 
parameter for selecting PpADI variants. Table S11 summarizes the vΔc,app  values of the 
generated PpADI variants at 100 μM arginine. Three SDM variants displayed increased vΔc,app 
values (M6+C30R: 0.055 μM·s-1, M6+C37R: 0.060 μM·s-1, M6+V291L: 0.055 μM·s-1), which is 
more than two times higher compared to M6 (0.027 μM·s-1) at 100 μM arginine. After 
recombination, two ‘best’ variants, M19 and M21 were finally selected (Figure 13 and Table 15) 
for kinetic characterization. Variant M21 with all the five beneficial substitutions has a more 
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than two times reduced S0.5 value (0.33 mM) compared to M6 (0.81 mM). Variant M19 exhibits 
a 3.6-fold higher catalytic activity (vΔc,app = 0.098 μM·s
-1) compared to parent M6 (0.027 μM·s-1) 
at arginine concentration of 100 μM.  
Table 15. Apparent kinetic constants (S0.5 values and v∆c,app) of PpADI variants. Experiments were performed with crude cell 
extracts. 
Mutants S0.5,app  
(mM) 
v∆c,app (μM·s
-1
)* 
[Arginine] =100 μM 
M6 (WT+K5T/D38H/D44E/A128T/E296K/H404R) 0.81±0.05 0.027±0.005 
M13 (M6+L148P) 0.45±0.04 0.041±0.008 
M14 (M6+K30R/C37R) 0.53±0.04 0.071±0.005 
M15 (M6+K30R/C37R/V291L) 0.46±0.02 0.082±0.005 
M16 (M6+K30R/C37R/G129S) 0.51±0.02 0.074±0.005 
M6+K30R 0.70±0.03 0.055±0.008 
M6+C37R 0.49±0.03 0.060±0.005 
M6+L148P 0.45±0.04 0.041±0.006 
M6+G129S 0.76±0.02 0.030±0.003 
M6+V291L 0.64±0.05 0.055±0.008 
M17 (M6+K30R/C37R/L148P) 0.42±0.04 0.087±0.005 
M18 (M6+K30R/C37R/G129S/V291L) 0.44±0.03 0.084±0.008 
M19 (M6+K30R/C37R/L148P/V291L) 0.35±0.03 0.098±0.003 
M20 (M6+K30R/C37R/G129S/L148P) 0.45±0.04 0.090±0.005 
M21 (M6+K30R/C37R/G129S/L148P/V291L) 0.33±0.03 0.096±0.005 
* Non-purified PpADI variants were used to measure the apparent activity (v∆c,app) at 100 μM arginine. 
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Figure 13. Genealogic tree of PpADI variants (WT to M21) with introduced amino acid substitutions. Five beneficial substitutions 
(K30R, C37R, G129S, L148P, and V291L) obtained from the two random mutagenesis (in this study) are highlighted in text in bold. 
Novel substitutions (compared to parent(s)) are indicated in text by asterisks. 
2.4.4. Determination of kcat and S0.5 values of PpADI WT, parent M6, ‘best’ variants M19 and 
M21 
The kcat and S0.5 values of PpADI WT, parent M6, and the improved variants (M19 and M21) 
were determined after purification. Kinetic characterization of PpADI variants was performed in 
PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4), which is 
regarded as an isotonic solution (Zhu et al. 2010a). PBS buffer maintains a constant pH (pH=7.4) 
and its osmolality and ionic strength mimics well physiological conditions (Zhu et al. 2010a). 
Figure 14 shows the kinetic curves of PpADI WT, parent M6 and the characterized variants fitted 
to the Hill equation (Gesztelyi et al. 2012; Zhu et al. 2010a). Both improved variants, M19 and 
M21, are improved in kcat and S0.5 for arginine depletion at pH 7.4 (see Table 2). M19 has a 
significantly decreased S0.5 value (0.35 mM) compared to parent M6 (0.81 mM) and WT (1.23 
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mM), and a higher kcat value (21.10 s
-1; 1.7-fold higher than parent M6 and 105.5-fold higher 
than WT); M21 has a significantly decreased S0.5 value (0.33 mM) to parent M6 and PpADI WT, 
and an increased kcat value of 18.27 s
-1, which is 91.4-fold higher compared to the PpADI WT. 
M19 displays among all variants the highest enzymatic efficiency (kcat/KM) (60.29 mM
-1·s-1; 3.8-
fold higher than parent M6 and 376.8-fold higher than WT) and activity at the plasma arginine 
concentration (100 µM arginine) vary between vM6 = 1.14 s
-1, vM19 = 2.66 s
-1, and vM21 = 2.64 s
-1 
(Table 2). Additionally, we confirmed that all PpADI variants produced > 99% L-citrulline (10 min 
incubation time; 1 mM (D, L)-arginine; 10 ng/µL PpADI variant; see Table 16). These results 
show that the introduced substitutions do not change the enantioselectivity of PpADI for L-
arginine. Finally, PpADI M19 was chosen for the anti-proliferation activity experiment for tumor 
cell line and compared to the references PpADI WT and PpADI M6.  
 
Figure 14. Kinetic curve of PpADI WT (●), parent M6 (■), M21 (□) and M19 (▲). 
Table 16. Kinetic constants of PpADI WT, parent M6 and the ‘best’ variants M19 and M21. 
 kcat [s
-1
] S0.5 [mM] kcat/S0.5 
[mM
-1
·s
-1
] 
v (s
-1
) * 
[Arg] = 100 μM 
e.e. [%] 
WT 0.20±0.02 1.23±0.16 0.16 n.d. > 99% (L) 
M6 11.90±0.66 0.81±0.08 15.66 1.14±0.13 > 99% (L) 
M19 21.10±0.19 0.35±0.02 60.29 2.66±0.16 > 99% (L) 
M21 18.27±0.23 0.33±0.02 55.36 2.64±0.19 > 99% (L) 
n.d. : no conversion detected. 
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2.4.5. Anti-proliferation activity of PpADI WT, parent M6 and the selected variant M19 
against two melanoma cell lines 
The in vitro anti-proliferation activity of PpADI WT, parent M6 and the improved variant M19 
was investigated with two arginine-auxotrophic human melanoma cell lines of SK-MEL-28 and 
G361. Varying concentrations of 0.01 µg/mL-10 µg/mL (final concentration) of purified PpADI 
WT, parent M6 and M19 were added to SK-MEL-28 and G361 cultures after 24 h cultivation in 
96-well MTPs. Over the next 6 days of incubation, cell viability assays were performed to 
determine the IC50 values. The IC50 values of PpADI WT towards SK-MEL-28 and G361 were 8.67 
and 4.85 µg/mL (Figure 15). Compared to WT, M6 showed a very significant decrease of IC50 
values against SK-MEL-28 and G361 cell line 0.10 µg/mL and 0.12 µg/mL, respectively, which 
means significantly improved anti-proliferation activity. M19 displayed the lowest IC50 value 
towards SK-MEL-28 (0.04 µg/mL; 0.45% of WT) and G361 (0.05 µg/mL; 0.93% of WT) cell lines 
(Figure 15) and it exhibited the strongest inhibition effect even when very low concentrations of 
the enzyme were used (0.10 µg/mL). The morphology analysis of melanoma cells which were 
treated with PpADI WT, M6 and M19 (0.10 µg/mL) for 6 days is shown in Figure 16. Under 
normal growth conditions SK-MEL-28 and G361 cells have a mixed triangular dendritic and 
elongated dendritic morphology, when studied at around 70% to 90% confluency in the 
photomicrographs (Figure 16). After treatment with 0.1 μg/mL PpADI WT for six days, living cells 
remained attached to the plate while dead cells detached, and the confluency rates decreased 
to ~50% (SK-MEL-28, Figure 16a) and ~60% (G361, Figure 16b). In addition, the confluency rates 
were decreased by treatment with 0.1 μg/mL PpADI M6 to ~15% both for SK-MEL-28 (Figure 
16a) and G361 (Figure 16b). Importantly, 0.1 μg/mL PpADI M19 induced extensive cell death 
(confluency of <10%), in both SK-MEL-28 and G361 as shown by morphology analysis (Figure 
16). 
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Figure 15. Dose-response curves of PpADI WT, M6 and M19 towards human melanoma SK-MEL-28 (A) and G361 (B) viability. SK-
MEL-28 (A) and G361(B) were grown in 96-well plates for 24 h and then treated with 0.01, 0.05, 0.1, 0.2, 0.4, 1, 2, 4, 8, and 10 
µg/mL (final concentrations) of purified and filter-sterilized PpADI WT (●), PpADI M6 (■), and PpADI M19 (▲), respectively. After 
six days, the viability of the tumor cells was determined using Cell Titer-Blue assay. 
 
Figure 16. Cell morphology of human melanoma cells SK-MEL-28 (a) and G361 (b) after treatment with PpADI WT and variants 
for six days. SK-MEL-28 cells were grown in 96-well plates for 24 h and then challenged with PpADI WT and mutants 6 days.  
2.5. Discussion 
A continuous assay -ADS was developed and validated by directed PpADI evolution towards 
physiological arginine concentrations. The newly developed ADS allows for a continuous 
detection of the activity of ADI at substrate concentrations as low as 0.1 mM which is 
significantly lower than the detection range of the previously reported citrulline colorimetric 
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assay (0.3–6 mM). The improved sensitivity can be attributed to a very low KM value of the 
glutamate dehydrogenase (from bovine liver) (Hudson and Daniel 1993) towards the released 
ammonia from the deamination step of the cascade reaction (Figure 8). In addition, the ADS 
eliminates the use of strong acid and simplifies handling when compared to the citrulline 
detection-based screening system (Zhu et al. 2010a). 
Previous attempts to engineer PpADI for activity improvement by directed evolution have 
resulted in several improved variants which has significantly increased kcat values (11.64 s
-1, 
PpADI M6) compared to PpADI WT (0.18 s-1) (Zhu et al. 2010a). Kinetic characterization revealed 
the necessity to further reduce KM values in order to exploit the potential of PpADI as 
therapeutic protein. Random mutagenesis and screening yielded five substitutions (K30R, C37R, 
G129S, L148P, and V291L) that confer the improvement in terms of activity (kcat) and affinity 
(S0.5) of PpADI towards arginine (Table 16). In order to determine the contribution of individual 
substitutions in decreasing the S0.5 value, these five substitutions were introduced individually 
into M6 through site-directed mutagenesis. Two substitutions (C37R and L148P) reduced the S0.5 
value, and three substitutions (C30R, C37R and V291L) significantly increased activity (measured 
as vΔc,app values at 100 μM arginine; Table 16). Interestingly, the introduction of V291L to the 
variants (M17 and M20) harboring the aforementioned substitutions (C37R and L148P) further 
decreased the S0.5 value (M19 and M21), whereas the substitution G129S led to a decrease in 
the S0.5 value (M6+G129S), but slightly decreased activity (vΔA340/s, app value in Table 16). The 
latter might explain why the substitution (G129S) does not show up in the ‘best’ variant (M19: 
M6+K30R/C37R/L148P/V291L). M19 has a very low S0.5 value (S0.5 = 0.35 mM) and a much higher 
kcat value (kcat = 21.10 s
-1) compared to M6 (kcat = 11.90 s
-1, S0.5 = 0.81 mM) and all other 
generated variants (see Table 16). Finally, M19 was selected for tumor cell line test to access its 
anti-proliferation activity. 
Preclinical investigations confirmed that ADI inhibited the proliferation of arginine-auxotrophic 
tumors (Gong et al. 2000; Gong et al. 1999). Our in vitro investigations of PpADI variants 
inhibiting the growth of melanoma cell lines demonstrate for the first time that reengineered 
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ADI variants show significantly enhanced inhibition effects against melanoma cell growth (SK-
MEL-28 and G361) compared to WT (Figure 16). PpADI variants M6 shows ~40-fold decreased 
IC50 value against G361 and 87-fold decreased IC50 value against SK-MEL-28 compared to PpADI 
WT. PpADI variant M19 showed a further reduced IC50 value compared to PpADI WT: 216-fold 
for SK-MEL-28 and 97-fold for G361. The dramatically decreased IC50 value of PpADI M19 allows 
using lower concentrations of this enzyme (i.e. lower dosages) to treat melanomas, e.g. of the 
SK-MEL-28 and G361 types. Compared to the published IC50 values of MhADI for melanoma 
cells, M19 displays a lower IC50 value than the MhADI (Ensor et al. 2002a) in inhibiting the 
growth of the G361 cell line (PpADI M19: 0.05 µg/mL; MhADI: 0.1 µg/mL). 
To gain deeper insights into the structural changes due to introduction of four newly identified 
amino acid substitutions (K30R, C37R, L148P, and V291L), homology models of PpADI variants 
were constructed. Figure 17 shows the model of PpADI M19 as a tetramer. The substitutions in 
the subunit A of M19 are represented in squares by using sphere format and loop1 (from R30 to 
I46) highlighted in pink color. Substitutions K30R and C37R, located in loop1 at the entrance of 
the substrate binding pocket (Figure 17), likely leaves more space for substrate arginine to enter 
the active site by increase the flexibility of R400 (in loop 4, located at the active site entrance 
and blocks the substrate binding site). The substitution of L148P, beneficial for lowering the S0.5 
value, is located at the interface between two monomers, for example, P148 in monomer A 
contacts with D272 in monomer D by a hydrogen bond (H-bond). A plausible hypothesis is that 
enhanced interactions between the monomers in tetrameric PpADI promote interactions with 
the substrate arginine at low concentrations. V291L is located at a β strand (from L290 to V293) 
closed to surface area and far away (>15 Å) from substrate arginine. Therefore, a molecular 
understanding on how the V291L substitution contributes to the decrease of the S0.5 value is 
challenging. Interestingly, a structure alignment of PpADI M19 with MaADI (KM= ~0.2 mM) 
shows that MaADI has also a leucine residue at position 283 (Das et al. 2004). This might 
indicate that leucine at this position (291 in PpADI and 283 in MaADI) is important for ADI to 
have a low KM value. For elucidating further the individual contribution of the four identified 
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amino acid substitutions to decreased S0.5 and increased kcat, the crystal structure of variant M19 
has to be solved. 
 
Figure 17. Structure model of PpADI M19 generated with FoldX software base on the model of PpADI M6. The tetrimetric 
structure of M19 is represented in cartoon-loop format. The substituted positions (in M19 subunit A) of R30, R37, P148, and 
L291 are highlighted in green, blue, blue and red, respectively. The loop1 (from R30 to I46) is highlighted in pink color. The 
substrate (arginine) and all the substitutions are shown in sphere format. 
2.6. Conclusions 
To sum up, an ammonia detection-based screening system (ADS) for ADI activity improvement 
at low arginine concentrations was developed and validated by identifying PpADI variants with 
improved activity at physiological arginine concentrations. Four amino acid substitutions were 
identified to reduce S0.5 values or increase kcat values. Moreover, the anti-proliferation activity of 
the improved PpADI variant M19 was investigated and compared to WT and M6 by in vitro 
experiments with two relevant melanoma cell lines under physiological conditions. The latter 
indicates that PpADI M19 is a highly attractive candidate to be used as therapeutic protein for 
the treatment of arginine-auxotrophic melanomas. Furthermore, the screening system based on 
ammonia detection can be used to improve other ADIs and very likely also other enzymes which 
produce ammonia, such as amidase or nitrilase. 
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3. Chapter III: Directed evolution of ADI based on a competitive flow cytometry 
screening system  
3.1. Declaration 
Parts of this chapter have been published in the journal ‘‘ACS Synthetic Biology’’. The usage of 
that paper is allowed from Copyright Clearance Center. 
3.2. Introduction 
Directed evolution is a powerful approach to tailor biocatalysts for industrial and therapeutic 
applications (Ruff et al. 2012; Zhu et al. 2010b). A major challenge in directed evolution 
experiments is the establishment of high-throughput screening systems for efficient coverage of 
the generated sequence space (Yang and Withers 2009). The screening systems in agar and 
microtiter plates typically enable an analysis of 104-105 events, which is several orders of 
magnitude below the size of a typical random mutagenesis library (108-109) (Yang and Withers 
2009). Recently, Flow cytometry has emerged as a powerful technology in directed evolution by 
enabling a throughput up to 107 events per hour (Dietrich et al. 2010). A key requirement for 
identifying improved enzyme variants by flow cytometry is the availability of fluorescent 
reporter systems with sufficient sensitivity and specificity. Flow cytometry based screening 
systems usually employ fluorogenic substrates (Ruff et al. 2012) or coupling to secondary 
reaction(s) to generate a fluorescent signal proportional to the specific enzymatic activity 
(Dietrich et al. 2010).  
Very recent, product-driven, transcription factor-based biosensors have been integrated in flow 
cytometry based screening systems for genomic screening (Binder et al. 2012), enzyme 
evolution (Schendzielorz et al. 2014; Siedler et al. 2014) and isolation of catabolic genes from 
metagenome libraries (Uchiyama et al. 2005). The employed transcription factors are regulated 
by product formation or accumulation within the host organism which in turn triggers the 
expression of a fluorescent protein (Schallmey et al. 2014). The generated fluorescence signal 
correlates to product formation within millimolar (mM) concentrations (Binder et al. 2012). 
However, such concentrations are one order of magnitude higher than those of many 
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metabolites in living cells or in blood plasma (e.g. in blood, [arginine] = ~100 µM) (Zhu et al. 
2010a). Therefore, it is essential to develop new flow cytometry based screening systems to 
reengineer enzymes by directed evolution for in vivo applications in which the substrate 
concentration is at micromolar (µM) level.  
In this section, a ligand-mediated eGFP-expression system (LiMEx) was developed as a novel 
flow cytometry for the detection of subtle differences in intracellular concentrations of 
metabolites. The described LiMEx screening platform relies on a competitive conversion/binding 
of arginine between arginine deiminase and arginine repressor. The principle of LiMEx was 
validated by evolving arginine deiminase for stronger inhibition of tumor growth. After 
screening of ∼8.2 × 106 clones in three iterative rounds of epPCR libraries, PpADI variant M31 
with reduced S0.5 value (0.17 mM compared to 1.23 mM (WT)) and enhanced activity at 
physiological arginine concentration (M31: 6.14 s−1; WT: not detectable) was identified. 
Moreover, M31 showed a significant inhibitory effect against SK-MEL-28 and G361 melanoma 
cell lines (IC50 = 0.02 μg/mL for SK-MEL-28 and G361). 
3.3. Materials and Methods 
3.3.1. Construction of arginine biosensor plasmid pArg-LiMEx 
Plasmid pArg-LiMEx (Figure 18) was constructed by introducing argR, argG and eGFP in 
pACYCDuet vector. First, high-fidelity PCR amplifications of argR, argG and eGFP were carried 
out according to the reaction and thermocycling conditons (as previous describe in section 
2.3.2) using the plasmid templates pDB169 (argR), pDIA539 (argG) and pEGFP (eGFP) and the 
respective primer pairs argRfwd/argRrev, argGProfwd/argGProrev and eGFPFwd/eGFPRev (Table 17). 
The primers were designed to introduce unique combinations of restriction sites to each 
amplified fragment. In the case of argR amplification, a T7 terminator sequence between the 
gene’s complementary sequence and the 3’-end restriction site was included in the respective 
reverse primer as well. Next, argR fragment with NcoI site at its 5’-end and a BamHI site at the 
3’-end was introduced in pACYCDuet by restriction cloning to obtain pACYCDuet-argR (Lim et al. 
1987; VanDuyne et al. 1996). pACYCDuet-argR-argGPro was constructed by introducing the 
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argG promoter (argGPro) DNA fragment in pACYCDuet-argR using restriction cloning and 
BamH/EcoRI cloning sites. Finally, eGFP fragment was inserted into pACYCDuet-argR-argGPro 
using EcoRI/HindIII restriction sites to form the arginine biosensor plasmid, pArg-LiMEx. 
Restriction digestion and ligation were carried out according to the manufacturer’s 
recommendations and chemically competent E. coli DH5α cells (New England Biolabs, Frankfurt, 
Germany) were used for the propagation of the intermediate and final genetic constructs. 
Table 17. Primers used for constructing pArg-LiMEx. 
Name Sequences (5’-3’) 
argR_fwd CATGCCATGGGCCGAAGCTCGGCTAAGCAAG 
argR_rev CGCGGATCCCAAAAAACCCCTCAAGACCCGTTTAGAGGCCCCAAGGGGTTATGCTAGTTAAAGCTCCTGGTCGAA
CAGCTC 
argGPro_fwd CCGGAATTCCGTTTATTGCTAATCATGTGAATG 
argGPro_rev GGGAAGCTTCATAAAATAACACCCTGCTTAATTAAC 
eGFP_fwd CCGCTCGAGTTACTTGTACAGCTCGTCCATGCC 
eGFP_rev CCGGAATTCTTTCAAATCCCACTACGAAG 
The underlined sequences indicate restriction sites sequences incorporated in PCR products for cloning purposes; the sequence 
in bold represents T7 terminator sequence. 
 
Figure 18. Schematic of the cloning strategy to generate pArg-LiMEx reporter. 
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3.3.2. Expression strains and media 
E. coli BL21-Gold (DE3) cells (Invitrogen, Karlsruhe, Germany) were used as host strain for all 
expression experiments. Cells harboring pArg-LiMEx were grown in 250 mL Erlenmayer flasks in 
a rotary shaker (INFORS HT, USA) at 37 °C, 250 rpm in arginine-free medium (Krin et al. 2003) 
(M9 minimal medium supplemented with glucose (0.05% instead of 0.5%) and a mixture of all 
proteinogenic amino acids (0.005% of each) except for L-arginine) or medium supplemented 
with varied concentrations of arginine. Co-expression (Tolia and Joshua-Tor 2006) of ArgR (pArg-
LiMEx-borne) and ADI (pET42a-borne) was carried out in the aforementioned media 
supplemented with chloramphenicol (34 µg/mL) and kanamycin (50 µg/mL) to maintain the 
presence of both plasmids over proliferation cycles. 
3.3.3. Characterization of pArg-LiMEx 
E. coli BL21-Gold (DE3) cells harboring pArg-LiMEx were grown in arginine-free media 
supplemented with varied concentrations of arginine (0 mM, 0.02 mM, 0.04 mM, 0.06 mM, 0.08 
mM, 0.1 mM, 0.15 mM, 0.2 mM, 0.3 mM and 0.4 mM). IPTG was added as an inducer to 
cultures after cell density (OD600) reached 0.6. The overall fluorescence (λex = 480 nm; λem = 505 
nm; gain 140)  in flat bottom black MTP was measured using Tecan Infinite M1000 Pro MTP 
reader (Tecan Group AG, Zürich, Switzerland) hourly after the adjustment of cell density (OD600 
equal 0.6). 
3.3.4. Optimization of LiMEx and identification of sorting parameters for flow cytometry 
BD Influx cell sorter (BD Biosciences, San Jose, CA) was used for cell analysis and sorting. The 
flow cytometer was fitted with a 100 µm nozzle and PBS was used as a sheath fluid. A sample of 
cells with pArg-LiMEx was diluted in ice-cold PBS buffer to an optical density below 0.1 and 
immediately analyzed and sorted according to the scatter characteristics (forward and side 
scatter) as well as to the fluorescent signal excited at 488 nm and emitted at a band pass filter 
at 530/40 nm. Cells were sorted with speed of 5000 events/s allowing a throughput of 1.8×107 
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events/h. During sorting, single cells were spotted onto LBkan/cm agar plates and then incubated 
later (37 °C for 12-14 h) until colonies formed. 
An optimized three-step transformation method was employed for introducing pArg-LiMEx and 
pET42b (+) into E. coli BL21-Gold (DE3). Firstly, the pArg-LiMEx was transformed into chemical 
competent E. coli BL21-Gold (DE3) cells to obtain E. coli BL21-Gold (DE3)/pArg-LiMEx. Secondly, 
competent cells of E. coli BL21-Gold (DE3)/pArg-LiMEx were prepared employing the Hanahan 
method (Hanahan et al. 1991). In the third step, competent E. coli BL21 Gold (DE3)/pArg-LiMEx 
cells were transformed with pET42b-ADI M21 or pET42b (empty vector). A single colony from 
each cell type was used to inoculate arginine-free media (37 °C). After reaching an OD600 value 
of 0.6, IPTG at final concentration of 0.4 mM was added and expression was carried for 6 h at 37 
°C. E. coli cells harboring pET42b-PpADI M21 or pET42b were mixed with ratios of 1:10, and 
1:100 (M21: EV; OD600 value ratios) as model libraries and then subjected to flow cytometry 
sorting as described in the previous paragraph.  
3.3.5. Protein expression and preparation of crude cell extracts in 96-well microtiter plate 
(MTP) 
Cultivation and expression of E. coli BL21-Gold (DE3)/pArg-LiMEx/pET42-PpADI in 96-well plates 
(v-bottom, transparent) were performed as previously described in 2.3.4. Cell lysis was 
performed by the addition of 80 µL lysozyme (final concentration: 80 µg/mL) to each well of 
MTP containing frozen cell pellet. The cell pellet was re-suspended by pipetting up and down 
and subsequently incubated at 37 °C for 20 minutes. After centrifugation at 4000 rpm for 15 
minutes (Eppendorf centrifuge 5804, Hamburg, Germany), the clarified supernatant was used 
for activity assays. 
3.3.6. Citrulline-detection system in MTP format 
Cell lysate (20 µL) of E. coli BL21-Gold (DE3)/pArg-LiMEx/pET42-PpADI was transferred into 96-
well MTP (flat bottom, transparent). The arginine conversion by PpADI was initiated by the 
addition of arginine solution (1 mM, pH 7.4, PBS buffer), and the mixture was incubated (20 
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min, 37 °C). Next, acid-ferric solution (Zhu et al. 2010a) (60 µL) and diacetyl monoxime (DAM, 20 
µL, 0.5 M) were added for citrulline detection. The reaction mixture was incubated for 30 min at 
55 °C. Absorbance was measured at 490 nm using a MTP reader (Tecan Sunrise, Tecan Group 
AG, Zürich, Switzerland).  
3.3.7. Ammonia-detection system (ADS) in MTP format 
Cell lysate (20 µL) of E. coli BL21-Gold (DE3)/pArg-LiMEx/pET42-PpADI was transferred into 96-
well MTP (flat bottom, transparent) which  were supplemented with 80 µL detection reagent 
(0.4 mM NADH, 5 mM α-ketoglutarate, and 5.55 U GDH) into each well, and the assay plates 
were incubated at 37 °C for 5 minutes. The cascade reaction was initiated by the addition of 100 
µL arginine solution (0.1 mM, pH 7.4, PBS buffer) and the absorbance at 340 nm was recorded 
by using a microtiter plate reader (Tecan Sunrise, Tecan Group AG, Zürich, Switzerland). The 
Beer-Lambert law was used for calculating the ammonia production velocity (v∆c) as previously 
described in section 2.3.5.1. 
3.3.8. PpADI error-prone PCR (epPCR) library generation and cloning 
Three high error-rate epPCR libraries (with 0.15 mM Mn2+) were generated using the master mix 
and thermocycling conditions the same as the description in section 2.3.2. The gene encoding 
PpADI M21 (K5T/K30R/C37R/D38H/D44E/A128T/G129S/L148P/V291L/E296K/H404R) was used 
as a template for the first round evolution. For the generation of the following rounds of epPCR 
library, the plasmids encoding 2 to 4 PpADI variants exhibiting the highest activity identified in 
the previous round of epPCR library were isolated, mixed at equimolar ratio and used as 
templates. The purified epPCR products were cloned into pET42b(+) vector by MEGAWHOP 
(Miyazaki and Takenouchi 2002).  
DpnI digested MEGAWHOP products were transformed into NEB 5-alpha electrocompetent E. 
coli cells (New England Biolabs, Frankfurt, Germany) and cells were spread onto LBkan agar plates 
(transformation efficiency > 109 CFU/mL). On the following day, the plasmid libraries were 
isolated from the colonies and transformed into E. coli BL21-Gold (DE3)/pArg-LiMEx (prepared 
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by transforming pArg-LiMEx in E. coli BL21 gold (DE3) and making the resulting strain competent 
using the Hanahan method (transformation efficiency > 108 CFU/mL)) (Hanahan et al. 1991). 
3.3.9. Site-directed mutagenesis for recombination of selected amino acid positions 
Site-directed mutagenesis of the PpADI at amino acid positions 74, 134, 136, 163, 193, 215, 288, 
and 312 was performed as previously described in section 2.3.5.2. Variants with recombined 
substitutions (identified in the three epPCR rounds) were generated using PpADI M27 as 
template (identified from the third epPCR library) using primers outlined in Table 18. The 
resulting PCR product was purified by using a PCR purification kit then digested with DpnI and 
transformed into E. coli BL21-Gold (DE3). 
Table 18. PCR primers used for site-directed mutagenesis. Substituted nucleotides are underlined). 
Name Sequences (5’-3’) 
N74S_fwd GTGCTGGAAATGCATAGCCTGCTCACCGATATC 
N74S_rev GATATCGGTGAGCAGGCTATGCATTTCCAGCAC 
E134G_fwd CAGGACCTGCCGGGGAGCGAAGGTGCCAGCGTGGTC 
E134G_rev GACCACGCTGGCACCTTCGCTCCCCGGCAGGTCCTG 
E136G_fwd CAGGACCTGCCGGGGAGCGGAGGTGCCAGCGTGGTC 
E136G_rev GACCACGCTGGCACCTCCGCTCCCCGGCAGGTCCTG 
F163S_fwd CTGCCCAACACCCAGTCCACCCGCGACACCACC 
F163S_rev GGTGGTGTCGCGGGTGGACTGGGTGTTGGGCAG 
T193A_fwd GAAACCCTGCTGACCGCCGCCATCTACAAGTTC 
T193A_rev GAACTTGTAGATGGCGGCGGTCAGCAGGGTTTC 
D215E_fwd GGTACGGCGACCCGGAGCAAGAGCACGGCCAG 
D215E_rev CTGGCCGTGCTCTTGCTCCGGGTCGCCGTACC 
R288H_fwd CAGCTTCTGCGACCACGACCTGCTCACGGGTTTC 
R288H_rev GAAACCCGTGAGCAGGTCGTGGTCGCAGAAGCTG 
K312R_fwd CGCCCGGACGAAAGCAGGCCCTACGGCATGGAC 
K312R_rev GTCCATGCCGTAGGGCCTGCTTTCGTCCGGGCG 
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3.3.10. Expression and purification of PpADI WT, parent M6 and the ‘best’ variant M31 
PpADI WT, PpADI M21 and variant PpADI M31 were expressed in shaking flasks and purified by 
anion-exchange chromatography (TOSOH, Stuttgart, Germany). PD-10 columns (GE Healthcare, 
Darmstadt, Germany) were subsequently used for desalting as previously described in section 
2.3.6. Protein concentrations after the final purification step were measured using the Thermo 
Scientific Pierce BCA protein assay kit (Rockford, IL, USA). 
3.3.11. Kinetic characterization of the purified PpADI variants 
The procedures of experiments of analysis in part were performed as previously described in 
section 2.3.7.  
3.3.12. Cultivation conditions for melanoma cell line cultures 
Two melanoma cell lines, SK-MEL-28 and G361, were cultivated at 37 °C, 5% CO2 in DMEM 
medium (Life Technologies, Darmstadt, Germany) supplemented with 10% fetal calf serum 
(FCS), nonessential amino acids (1×), pyruvate (1×), 100 µg/mL streptomycin, and 100 µg/mL 
penicillin. 
3.3.13. Cell proliferation assay 
This part of experiments was performed as previously described in section 2.3.10.  
3.4. Results  
In section 3.4.1 to 3.4.3, a flow cytometry based screening system was developed for the 
detection of subtle differences in intracellular concentrations of metabolites. The ligand-
mediated eGFP-expression system (LiMEx) establishes a competitive relationship between the 
regulation of a fluorescent protein expression (e.g. eGFP) by an effector molecule (e.g. arginine) 
and the biochemical depletion of the effector by a co-expressed recombinant enzyme (e.g., 
arginine deiminase). The fluorescence intensity of the fluorescent protein therefore serves to 
quantify enzymatic performance. The arginine-based LiMEx (termed Arg-LiMEx) described in 
this part as a prototypic example, takes advantage of the regulation of arginine biosynthesis in E. 
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coli which synthesizes arginine from citrulline by employing argininosuccinate synthetase (ASS) 
and argininosuccinate lyase (ASL) (Figure 19a, green box) (Krin et al. 2003). The transcription of 
argG (which encodes ASS) is modulated by the arginine repressor (ArgR). With arginine as co-
repressor, ArgR tightly binds to the argG promoter region (Krin et al. 2003; VanDuyne et al. 
1996) and efficiently suppresses eGFP expression (under the control of argG promoter). eGFP 
fluorescence can therefore be correlated to intracellular arginine concentrations which are 
determined by the performance of a co-expressing arginine metabolizing enzyme PpADI (Figure 
19a, blue box). Furthermore, Arg-LiMEx screening platform was validated by sorting of two 
model populations under physiological conditions ([arginine] = ~0.1 mM, pH =~7.4 and 37 °C) in 
section 3.4.4. Moreover, in section 3.4.5-3.4.6, the Arg-LiMEx screening platform was applied 
for three iterative rounds of directed evolution in which PpADI was subjected to high mutational 
loads (~92% inactive variants; ~5 nucleotide exchanges per gene). Finally, the characterization 
results of the ‘best’ variant PpADI M31 were shown in section 3.4.7. 
 
Figure 19. Principle of eGFP-based arginine sensor encoded by pArg-LiMEx. (a) Schematic outline of the arginine biosynthetic 
pathway in E. coli (green box), the ADI deimination reaction (blue box) and the role of arginine which is the co-ligand for ArgR 
and ADI (red box). (b) The pArg-LiMEx vector encodes the Arg-LiMEx for quantifying arginine at micromolar concentrations (100 
to 500 µM) in cells. The pArg-LiMEx vector comprises an ArgR under the control of a T7 promoter and an eGFP gene under the 
regulation of an argG promoter.  
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3.4.1. Construction of pArg-LiMEx vector (the biosensor) 
The pArg-LiMEx vector (Figure 19b) was designed as a biosensor for quantification of arginine at 
micromolar concentrations. The biosensor comprises argR gene (encoding a repressor protein 
ArgR) under the control of a T7 promoter and egfp gene under the control of an argG promoter; 
ArgR serves to regulate argG promoter function and, consequently, eGFP expression. IPTG and 
arginine concentrations are the two extrinsic factors that can modulate the expression level of 
eGFP. Therefore, an experiment was performed to determine an optimized IPTG concentration 
at which eGFP expression is altered solely by subtle changes in arginine concentration. E. coli 
cells transformed with pArg-LiMEx were grown in arginine-rich media and the magnitude of 
fluorescence signals (generated by eGFP) were monitored over time (Figure 20). In the time 
prior to ArgR expression, eGFP accumulated and the fluorescence signal of E. coli cells increased 
to ~600 Relative Fluorescence Units (RFU). After induction of the argR expression by varied 
concentrations of IPTG (0 to 800 µM), an IPTG concentration-dependent fluorescence signal 
decrease was observed. A maximal repression of eGFP was achieved when ≥ 100 µM IPTG was 
employed (Figure 20a) and the highest over expression of ArgR was obtained by induce of 0.4 
mM IPTG (Figure 20b). To ensure a robust performance, 400 µM IPTG was selected in further 
experiments. Remarkably, despite the host strain, E. coli BL21(DE3) (genotype: E.coli B F– ompT 
gal dcm lon hsdSB(rB
- mB
-) λ(DE3)), contains endogenous ArgR, the expression level of 
endogenous ArgR repressor was too low to effectively repress eGFP express, in the presence of 
100 µg/mL arginine (ArgR should be > 31% of total protein amount; Figure 20b). 
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Figure 20.  (a) Change of fluorescence intensity over time (0-10 h after IPTG addition) of E. coli BL21 harboring pArg-LiMEx in 
arginine-rich media supplemented with varied IPTG concentrations (0 - 800 µM), (b) ArgR expression level in arginine-rich media 
after 6 h induce by different concentrations of IPTG (0 µM, 1 µM, 10 µM, 100µM, 400 µM and 800 µM). The analysis was done 
by Experion automated gel electrophoresis system with Experion Pro260 Analysis kit (Bio-Rad). The percentages of ArgR 
concentration to total protein concentration are shown. 
3.4.2. Characterization of pArg-LiMEx 
Initially, the applicability of Arg-LiMEx for transforming a given intracellular metabolite 
concentration into an optical output was tested by investigating the relationship between 
arginine concentration and eGFP fluorescence intensity. E. coli cells were transformed with 
pArg-LiMEx and grown in arginine-free media supplemented with varying concentrations of 
arginine (from 0 to 0.4 mM). In the time prior to ArgR expression, eGFP accumulated, thus the 
fluorescence signal of E. coli cells increased over time to an RFU of ~600. The time of induction 
was used as reference time point (0 h) in Figures 20 and 21. After the induction of ArgR 
expression, a distinct arginine concentration dependent decrease of fluorescence signal was 
observed after ~2 h, whereas the fluorescence signal of the positive control (no IPTG addition; 
no ArgR expressed) continued to increase (Figure 21a). The most pronounced differences in 
fluorescence intensity between induced and non-induced samples were observed after 6 h 
(Figure 21a). The linearity of fluorescent signal was maintained for extracellular arginine 
concentrations between 0 and 0.1 mM (Figure 21b), corresponding to an intracellular 
concentration range of ~0.1-0.5 mM (Figure 21a); a range that adequately covers the arginine 
level in blood plasma (100-120 µM). eGFP-based fluorescence did not decrease further at 
extracellular arginine concentrations ≥0.1 mM. These values are consistent with published in 
vitro studies of ArgR inhibition strength (Krin et al. 2003). Another experiment performed to test 
the change in ArgR expression level over time showed that the expression level of ArgR was not 
affected by varying arginine concentrations (0 - 0.4 mM arginine) (Figure 22b). In addition, no 
significant changes in cell growth rates were observed as a result of the varied arginine 
concentrations (Figure 22a) which is likely because that the arginine is non-essential amino acid 
for E.coli. These results indicate that the weak repression of GFP production at 0 mM arginine 
was neither due to lower expression rates of ArgR nor was caused by different cellular growth 
rates, but when there is 0 mM arginine in growth media, there is ~0.1 mM arginine in the E.coli 
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cells based on (Caldara et al. 2008). The low intracellular arginine concentration will lead to low 
repression of GFP. Taken together, the preliminary tests indicated that the monitoring of 
physiological arginine concentration (arginine concentration: 100-120 µM; pH ~7.4) is feasible 
with the pArg-LiMEx. 
 
Figure 21. Characterization of the arginine sensor (a) The fluorescence intensity of non-induced and IPTG-induced E. coli cells 
harbor pArg-LiMEx (OD600 = 0.6). Cells were grown in arginine-free media supplemented with varying concentrations of arginine 
(from 0 to 0.4 mM). Prior to IPTG induction, eGFP was constitutively produced under the control of the argG promoter. 
Fluorescence intensities of induced E. coli cells gradually decreased over time and in response to arginine concentrations. The 
fluorescence intensity of the positive control (non-induced, no ArgR expressed) increased until ~6 h after IPTG addition (~9 h 
cultivation time). (b) Fluorescence intensities of induced cells in media with varied concentrations of arginine (from 0 mM to 0.4 
mM; time point 6 hours after IPTG addition). A decrease in fluorescence was observed between 0 and 0.1 mM arginine. 
 
Figure 22. (a) The growth curve of E. coli BL21 (DE3) in arginine-free media with different arginine concentrations (0 mM, 0.1 
mM, 0.2 mM, 0.4 mM), (b) ArgR expression level over time (after IPTG addition) in arginine-free media with different arginine 
concentrations (0 mM, 0.1 mM, 0.2 mM, 0.4 mM). The analysis was done by Experion automated gel electrophoresis system 
with Experion Pro260 Analysis kit (Bio-Rad). The percentages of ArgR concentration to total protein concentration are shown. 
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3.4.3. Development of pArg-LiMEx based ultrahigh-throughput screening system 
These findings prompted us to develop a pArg-LiMEx based ultrahigh-throughput screening 
system for screening PpADI variants with improved activity under physiological conditions (e.g. 
pH ~7.4 and arginine concentration from 100 to 120 µM). The connection between competitive 
arginine binding, conversion and fluorescent read out of the Arg-LiMEx is shown in Figure 23a, 
and the screening strategy is outlined in Figure 23b. First, the influence of IPTG concentration 
on fluorescence intensity of eGFP was tested in 96-well microtiter plate (Figure 24). 400 µM 
IPTG led to the most significant difference in fluorescence intensity between PpADI WT and 
M21 after 6 h induction (Figure 23c) and highest over expression of ArgR. Therefore, 400 µM 
IPTG was used for following experiments. Next, in order to establish flow cytometry sorting 
parameters, a comparison of four populations (negative control, PpADI wild type (WT, kcat = 0.18 
s-1), PpADI M21 (kcat = 18.27 s
-1; ~100-fold higher kcat than WT), positive control) was analyzed by 
flow cytometry (6 h after IPTG induction) (Figure 23d). Cells co-transformed with pArg-LiMEx 
and pET (‘Empty Vector’ EV, no ADI insert) and non-induced E. coli cells harboring pArg-LiMEx 
served as negative and positive controls, respectively. The negative control (no PpADI 
expressed) has the lowest mean fluorescence value (Fmean = 7; calculated from 10,000 events) 
and the positive control (no ArgR expressed) exhibited the highest mean fluorescence value 
(Fmean = 90) (Figure 23d). In the Arg-LiMEx screening host, the expression of PpADI WT resulted 
in a mean fluorescence value of 8 (slightly above the negative control due to its low activity), 
while PpADI M21 yielded a mean fluorescence value of 19 (10,000 events) (Figure 23d). M21’s 
higher mean value than WT’s, and the distinct population of their populations, indicated that 
active PpADI variants can be distinguished from the low active ones by flow cytometry analysis.  
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Figure 23. The Arg-LiMEx ultrahigh-throughput screening system. (a) Detection principle of the Arg-LiMEx system. eGFP 
fluorescence depends on intracellular arginine concentration which is determined by PpADI’s performance in converting 
arginine. Top panel: eGFP expression is inhibited when the argG promoter is blocked in presence of arginine by the ArgR-
arginine-ArgR complex; Bottom panel: eGFP is produced when PpADI can efficiently deplete the intracellular arginine. (b) The 
procedure of directed PpADI evolution: (i) mutant library generation by epPCR; (ii) transformation of mutant library into E. coli 
cells with the reporter pArg-LiMEx; (iii) to (v) pre-screening of PpADI mutant library with the Arg-LiMEx system using flow 
cytometer; (vi) rescreening of PpADI variants in 96-well MTPs; (vii) and (viii) identification and characterization of improved 
PpADI variants. (c) Fluorescence intensities show that PpADI M21 can be distinguished from PpADI WT using LiMEx in MTP. 
Positive control (green) performed with non-induced E. coli cells harboring pArg-LiMEx (no ArgR expressed). Negative control 
(blue) performed with E. coli cells harboring pArg-LiMEx and EV (no ADI expression). (d) Flow cytometry analysis of four 
populations and their distribution (negative control (blue), ADI WT (yellow), ADI M21 (red) and positive control (green)). Images 
on top show overlays (transmission and fluorescence images) of E. coli cells that were recorded by confocal microscopy. 
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Figure 24. The fluorescence intensities of E. coli cells harboring pArg-LiMEx and PpADIs in arginine-free media with different 
IPTG concentrations (0 mM (a), 100 µM (b), 200 µM (c), 400 µM (d)). Positive control performed with non-induced E. coli cells 
harboring pArg-LiMEx (no ArgR expressed). Negative control performed with E. coli cells harboring pArg-LiMEx and EV (no ADI 
expression). 
3.4.4. Sorting of model populations by Arg-LiMEx ultrahigh-throughput screening system 
Enrichment factors were determined by sorting model populations comprising mixtures of E. 
coli cells harboring either PpADI M21 or empty vector (EV). The EV and PpADI M21 were grown 
separately in arginine-free media, harvested (6 hours after IPTG induction), mixed at a ratio of 
1:10 or 1:100 (M21: EV) and subjected to flow cytometric analysis and sorting. E. coli cells 
harboring PpADI M21 were well separated from the negative control (EV; no ADI) by the P1 gate 
which captured 0.01% of the negative control (EV) and 9.6% or 1.2% of the model populations 
(1:10 or 1:100; Figure 25). Sorted cells were grown onto agar plates and transferred into MTPs 
for detailed quantification of activity employing the citrulline quantification assay (in section 
3.3.6). The enrichment factors of the two sorted model populations were 11.3-fold (the 
active/inactive ratio from 8.3% to 93.8%) and 91.7-fold (from 1.0% to 91.7%), which validated 
the availability of Arg-LiMEx screening system with the selected sorting gate (Figure 25). In 
addition, sorting of model populations were performed by comprising mixtures of PpADI M6 
(kcat = 11.64 s
-1) and PpADI M21 (kcat = 18.27 s
-1) at ratios of 1:10 and 1:100, respectively. The 
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enrichment factors of the two sorted model populations, from sequencing results, were 9.2-fold 
(PpADI M21: PpADI M6 = 1:10) and 87.5-fold (PpADI M21: PpADI M6 = 1:100), respectively. 
These results further validated the Arg-LiMEx screening system is able to distinguish between 
PpADI variants with 1.6-fold difference in kcat value. 
3.4.5. PpADI error-prone PCR (epPCR) library generation and screening by Arg-LiMEx 
PpADI M21 was used as a parent variant for validation of the Arg-LiMEx screening platform in 
three iterative rounds of directed evolution (89%-92% inactive variants; mutation frequency of 
~5 nucleotide exchanges per gene) using the procedure outlined in Figure 23b and the stringent 
gate P1 during sorting by flow cytometry (Figure 25). Initially, PpADI activity was detected in 
~90% of all sorted cells and ~30% of the sorted populations showed at least a 1.5-fold 
improvement compared to the parent M21. Two variants (M22 and M23, Figure 26) exhibiting 
the highest activities (vΔc) at 100 µM arginine (Table 19) were selected as templates for the 
second round of evolution and the variants M24, M25, and M26 were chosen for the third 
round of directed evolution. After the third round of directed evolution, four variants (M27 to 
M30) were isolated, sequenced and subjected to kinetic characterization using crude cell 
extracts. All four PpADI variants contained unique mutations and not only improved catalytic 
rate but reduced S0.5 (‘KM’) values as well (Table 19). Variant M27 (M21+E39G/F42Y/V293I) was 
further reengineered by introducing the beneficial amino acid substitutions (namely, N74S, 
K312R, R288H, T193A, E134G, E136G, D215E and F163S) identified in three rounds of epPCR 
(Figure 26) (kcat and S0.5 values in Table 19). Finally, PpADI M31 
(M21+V293I/F42Y/E39G/K312R/N74S/T193A/E134G/E136G) was identified as the most 
improved PpADI variant with significantly reduced S0.5,app values (0.17 mM) and increased 
catalytic activity (v∆c,app = 3.096 μM·s
-1) at the physiological arginine concentrations (100 µM 
arginine) (Table 19). 
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Figure 25. Flow cytometer sorting of the first epPCR mutant library (PpADI M21 as parent). Sorting procedure is shown in (a), 
the sorting gate P1 (< top 5% of fluorescent population) in (b), positive control (no ArgR expression) in (c), and negative control 
(EV, no ADI expression) in (d). Color coding in Figure (b), (c), and (d) is according to occurrence from blue (few events) to red 
(many events).  
Table 19. Apparent kinetic constants (S0.5,app) of PpADI variants (experiments were performed with crude cell extracts). 
Mutants  
 
S0.5,app  
(mM) 
v∆c,app (μM·s
-1
)* 
[Arginine] =100 μM 
M21 (WT+K5T/K30R/C37R/D38H/D44E/A128T 
/G129S/L148P/V291L/E296K/H404R) 
0.33±0.03 0.10±0.01 
M22 (M21+P163S/D215E) 0.32±0.02 0.13±0.02 
M23 (M21+V293I) 0.26±0.01 0.15±0.01 
M24 (M23+F42Y) 0.24±0.02 0.22±0.01 
M25 (M23+E134G) 0.24±0.04 0.22±0.01 
M26 (M23+E136G) 0.23±0.02 0.22±0.01 
M27 (M24+E39G) 0.19±0.02 0.30±0.02 
M28 (M24+N74S) 0.23±0.01 0.30±0.01 
M29 (M25+K312R) 0.23±0.02 0.25±0.01 
M30 (M25+T193A/R288H) 0.23±0.02 0.25±0.02 
M31 (M21+V293I/F42Y/E39G/K312R/N74S/T193A/ 
E134G/E136G) 
0.17±0.01 0.31±0.02 
*Clear supernatants of PpADI variants were used to measure the apparent activity (v∆c,app) at 100 μM arginine. Initial velocities 
were calculated from the slope at 340 nm (vΔA) in flat-bottom MTP. An equation (vΔA = ε × b × vΔc) based on Beer-Lambert law 
was used for calculating the ammonia production velocity (vΔc), and further obtaining the activity of PpADI. Absorption 
coefficient (ε) of NADH is 6,200 M
-1
 cm
-1
. Liquid height (b) in each well of MTP is approximately 0.59 cm (total volume of 
reaction mixture in each well of MTP is 200 μL). 
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Figure 26. Genealogic tree of PpADI variants (WT to M31) with generated amino acid substitutions and key performance 
parameters. 
3.4.6. Determination of kcat and S0.5 values of purified PpADI WT, parent M21, ‘best’ variant 
M31 
Kinetic characterization of three purified PpADIs (PpADI WT, PpADI M21 (parent), and PpADI 
M31) (Table 20) were performed under conditions which mimic blood plasma environment 
(~0.1 mM arginine, PBS buffer pH 7.4: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4). M31 exhibited the lowest S0.5 value (0.17 mM), the highest kcat value (26.37 s
-1), the 
highest enzymatic efficiency (kcat/KM) (155.12 mM
-1·s-1; 2.8-fold higher than parent M21 and 
969.5-fold higher than WT), and most significantly the highest reported activity at 100 µM 
arginine (vM21 = 2.64 s
-1, vM31 = 6.14 s
-1) (Table 20). 
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Table 20. Kinetic constants of PpADI WT, parent M21 and the ‘best’ variant M31. 
 kcat [s
-1
] S0.5 [mM] kcat/S0.5 [mM
-1
·s
-1
] v (s
-1
) at [arginine] = 100 μM 
WT 0.20±0.02 1.23±0.16 0.16 n.d. 
M21 18.27±0.23 0.33±0.02 55.36 2.64±0.19 
M31 26.37±0.66 0.17±0.02 155.12 6.14±0.13 
n.d. : no conversion detected. 
 
3.4.7. Anti-proliferation activity of PpADI WT, parent M21, ‘best’ variants M31 against two 
melanoma cell lines 
Two arginine-auxotrophic human melanoma cell lines (SK-MEL-28 and G361) were selected to 
evaluate the in vitro anti-proliferation activity of M31. The half-maximal inhibitory 
concentrations (IC50) of M31, PpADI WT and M21 were determined (WT: 8.19 µg/mL for SK-
MEL-28 and 4.48 µg/mL for G361; M21: 0.06 µg/mL for SK-MEL-28 and 0.07 µg/mL for G361; 
M31: 0.02 µg/mL for SK-MEL-28 and G361). In summary, M31 exhibited the lowest IC50 value 
against the SK-MEL-28 (0.02 µg/mL; 0.24% of WT) and G361 (0.02 µg/mL; 0.45% of WT) cell lines 
(Table 21) and displayed a strong inhibition effect even at a low enzyme dosage (0.08 µg/mL, 
Figure 27).  
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Figure 27. Cell morphology of human melanoma cells SK-MEL-28 (a) and G361 (b). SK-MEL-28 and G361 were grown in 96-well 
plates (24 h; pH 7.4, DMEM media). Pictures were recorded six days after supplementing buffer (upper left pictures), 0.08 µg/mL 
of PpADI WT (upper right), M21 (lower left), or M31 (lower right).  
Table 21. Determination of IC50 values of PpADI WT, M21 and variant M31 toward human melanoma cell (SK-MEL-28 and G361) 
proliferation activity. Both melanoma cell lines were grown in 96-well plates for 24 h and then subjected to 0.01, 0.05, 0.1, 0.2, 
0.4, 1, 2, 4, 8, or 10 µg/mL of PpADI WT, M21 or M31 for an additional 6 days. The IC50 values listed here were calculated by 
GraphPad Prism software. 
Variants 
IC50 (µg/mL) 
toward SK-MEL-28 
Variants 
IC50 (µg/mL) 
toward G361 
WT 8.19±0.56 WT 4.48±0.43 
M21 (parent) 0.06±0.01 M21 (parent) 0.07±0.01 
M31 0.02±0.01 M31 0.02±0.01 
 
  
Chapter III: Directed evolution of ADI based on a competitive flow 
cytometry screening system 
 Page 63 
 
3.5. Discussion 
A ligand-mediated eGFP-expression system (LiMEx) was developed as a novel flow cytometry 
based screening platform that relies on a competitive conversion/binding of arginine between 
arginine deiminase and arginine repressor. Unlike product-driven detection systems, the 
competitive screening platform allows to evolve enzymes toward efficient operation at low 
substrate concentrations under physiological conditions. The principle of LiMEx was validated by 
evolving arginine deiminase for stronger inhibition of tumor growth. After screening of ∼8.2 × 
106 clones in three iterative rounds of epPCR libraries, PpADI variant M31 with reduced S0.5 
value (0.17 mM compared to 1.23 mM (WT)) and, importantly, increased activity at 
physiological arginine concentration (M31:6.14 s−1; WT: not detectable) was identified. 
Moreover, M31 showed a significant inhibitory effect against SK-MEL-28 and G361 melanoma 
cell lines. (IC50 = 0.02 μg/mL for SK-MEL-28 and G361). 
Arg-LiMEx represents a novel generation flow cytometry based screening platform for the 
identification of arginine metabolizing enzymes at low arginine concentrations that amply 
reflect physiological conditions. Arg-LiMEx biosensor differs from the existing product-driven 
flow cytometry based screening systems in its mode of regulation of reporter’s expression and 
possible applications. In product-driven screening systems, the generated fluorescence signal is 
proportional to product formation, i.e. when the concentration of product is very low, the 
fluorescence signal is also low compared to the signal obtained when the product concentration 
is high. It could lead to non-reliable detection when the transcription factor has low response to 
the product. In LiMEx, a reverse proportionality was established. The decrease of the 
ligand/substrate concentration translates into the gain of fluorescence signal (Figure 21b). This 
is due to the biosensor’s design wherein a competition between the metabolite’s enzymatic 
depletion and its role in the regulation of reporter expression governs the magnitude of the 
output signal. Therefore, LiMEx offers a novel concept for screening of enzymes for efficient in 
vivo conversion of substrates at low concentration (µM range). For example, this Arg-LiMEx 
platform could be further applied for identification of improved arginases (powerful 
therapeutics against arginine-auxotrophic HCCs and melanomas (Cheng et al. 2007)), and nitric 
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oxide synthases (applied for vascularized tumors (Zheng et al. 2007)). Furthermore, the 
competitive selection principle of LiMEx is not limited to arginine and can very likely be 
extended to other metabolites or compounds in which a repressor is activated at a low 
concentration. Some therapeutic enzymes that could be conceptually evolved via LiMEx are 
shown in Table 22. For instance, asparaginase, a drug for treatment of leukemia (Broome 1981), 
could be evolved by an ‘Asp-LiMEx system’ based on a competition between L-asparagine 
operon repressor (AnsR) and asparaginase towards asparagine (physiological concentration ~0.1 
mM). Additionally, the variant PpADI M21 was generated after screening 9,300 clones in four 
rounds of evolution in a time span of 3 years. Three rounds of evolution (in total 8.2 million 
variants) were performed to generate M31 by Arg-LiMEx within six months (Figure 26). 
Table 22. Selected examples of therapeutic enzymes which could be analyzes by LiMEx. 
Enzyme Ligand Transcription factor Treatment of disease 
arginine deiminase 
 
arginine Arginine repressor (ArgR) arginine-auxotrophic HCCs 
and melanomas, leukemia, 
glioblastoma, prostate 
cancer, small cell lung cancer 
arginase 
 
arginine Arginine repressor (ArgR) arginine-auxotrophic HCCs 
and melanomas 
nitric oxide 
synthases 
arginine Arginine repressor (ArgR) vascularized tumors 
asparaginase asparagine asparagine operon repressor 
(AnsR) 
leukemia 
adenosine 
deaminase 
adenosine 3',5'-
monophosphate 
Adenosine 3',5'-
monophosphate early 
repressor (ICER) 
severe combined 
immunodeficiency 
urate oxidase uric acid allantoin repressor (AllR) refractory chronic gout 
 
Additionally, IC50 values of the reported MhADI have been determined in the context of 
melanoma cell proliferation and PpADI M31 showed a five times lower IC50 value of the 
commercial MhADI (0.1 µg/mL towards G361) (Ensor et al. 2002b). In comparison to other 
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therapeutic enzymes, e.g. the recombinant human arginase (in phase II clinical trials for 
hepatocellular carcinoma (HCC)) (Cheng et al. 2007), PpADI M31 displays a 21-fold lower IC50 
value for the SK-MEL-28 cell line (PpADI M31: 0.02 µg/mL; rhArg: 0.42 µg/mL) (Cheng et al. 
2007). 
3.6. Conclusions 
In summary, a flow cytometry-based screening system (Arg-LiMEx) for screening of arginine- 
metabolizing enzymes at low arginine concentrations was developed and validated by 
identifying PpADI variants with improved activity at physiological arginine concentrations. Arg-
LiMEx represents a novel generation flow cytometry based screening platform for the 
identification of arginine metabolizing enzymes at low arginine concentrations that amply 
reflect physiological conditions. PpADI M31 was finally identified with reduce S0.5 value and 
increase kcat value. Moreover, the anti-proliferation activity of the improved PpADI variant M31 
was investigated and compared to WT and M21 by in vitro experiments with two relevant 
melanoma cell lines under physiological conditions. The latter indicates that PpADI M31 is a 
highly attractive candidate to be used as therapeutic protein for the treatment of arginine-
auxotrophic melanomas.  
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4. Chapter IV: Loop engineering of PpADI revealed the importance of loop1, 
loop4 and Arg400 in modulating substrate affinity  
4.1. Introduction 
Loops, belonging to the most flexible parts of enzyme structures, are a diverse class of 
secondary structures comprising turns, random coils, and strands which connect the main 
secondary structures (α-helices and β-strands). Due to the high mobility of loop regions, 
interactions of enzymes with substrates and cofactors require conformational changes often 
involving the residue (located on loop regions) side chains capable of adopting different 
rotamers or external loops located in the periphery of the active site (Nestl and Hauer, 2014). 
For example, a flexible loop I (residues 9-24) in a dihydrofolate reductase from E. coli, plays a 
funcational role in hydrophobic interaction with the nicotinamide and pteridine rings for the 
hydride-transfer process (a form of transition-state stabilization) (Li et al. 1992). The deletion of 
the central residues (Met16-Ala19) in the loop I, resulted in a remarkable ~550-fold decrease in 
the rate of hydride transfer. Furthermore, loops exposed on the surface/interface of enzyme 
can also plays a vital role in protein functions, primarily because they can undergo considerable 
structural changes while interacting with the ligand molecules and solvent.  
Protein engineering studies have revealed that the target enzyme properties, such as high 
activity, robust thermostability and high enantioselectivity, could be achieved by engineering of 
important residues in loop regions. Shivange et al. used protein engineering strategy improved 
thermal resistance and specific activity of a phytase from Yersinia mollaretii (Ymphytase) 
(Shivange et al. 2012) by substitution of residues in loop regions. In detail, two random 
mutagenesis libraries were generated (epPCR and SeSaM), ~9000 clones were screened and 5 
beneficial positions (D52, T77, K139, G187, V298) were identified by subsequent individual site 
saturation mutagenesis. Computational analysis showed that D52 and T77 are located in the 
loops next to the active site. The final variant Omni1 harboring the substitution of D52N and 
T77K showed a 41 U/mg improved activity, a 2 °C increased Tm and a 2-fold higher pH stability 
(at pH 2.8) (Shivange et al. 2014). Further analysis of Ymphytase WT and Omni1 showed a salt-
bridge (introduced by T77K) reduced the overall dynamics Ymphytase, especially the flexibility in 
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the loops). Interestingly, the local flexibility of a loop closed to the active site was increased by 
the substitution D52N which likely contributed to the higher specific activity. 
To better understand the dynamical effects of the loop regions, molecular dynamics (MD) 
simulations are utilized for study the protein conformational changes over small time 
increments (in ps/ns range). By calculating the root mean square deviation (RMSD) and root 
mean square fluctuation (RMSF) values of important amino acid positions/regions, several 
conformationally flexible regions of a protein can be identified. Using MD simulations, Tian et al. 
identified a flexible loop region (residues 186–193) of methyl parathion hydrolase from 
Ochrobactrum sp. M231. The variant G194P (a Gly residue nearest to this region was mutated to 
Pro) showed decreased conformational fluctuation in the loop region and thus increased the 
thermostability (Tm value increased from 67.0 °C to 70 °C). 
The objective of this chapter was to identify important amino acid positions, in loop1 and loop4 
of PpADI, which were beneficial for lowering the KM value. Homology modeling and MD 
simulation methods were employed to understand and rationalize the structural and dynamical 
property of this tetrameric ADI and its variants. The work described in Chapter II and III showed 
that the kinetic properties of PpADI were dramatically improved by directed evolution (five 
rounds of random mutagenesis to identify favorable substitutions, and followed by SDM for 
recombination). However, the S0.5 (‘KM’) value of PpADI M31 (~0.2 mM) is still 2-fold higher than 
the physiological arginine concentration (~0.1 mM), and significantly higher than that of MaADI 
(~4 µM) (Das et al. 2004). A reduction of PpADI’s S0.5 value from 0.2 mM to 0.1 mM would result 
in a ~2-fold velocity increase at 100 µM arginine. From the evolution pathway (Genealogic tree 
in Figure 27), 18 potentially beneficial positions responsible for S0.5 or kcat improvement were 
identified. After visual inspection of PpADI’s model, it was observed that 7 out of 18 are located 
on loop1 or loop4 (the active site of the PpADI is surrounded by four loops (loop1: 30–46, loop2: 
178–185, loop3: 271–281, and loop4: 393–404) (Zhu et al. 2010b)). Two high-throughput 
screening systems (based on MTP format and flow cytometry, as described in section 2.4.1 and 
3.4.3) were developed, which enable a throughput up to 107 events per hour and a 
straightforward kinetic analysis. 
Chapter IV: Loop engineering of PpADI revealed the importance of 
loop1, loop4 and Arg400 in modulating substrate affinity 
 Page 68 
 
4.2. Materials and Methods 
4.2.1. Molecular modeling and molecular dynamics simulations of the PpADI WT and variants 
In order to gain first insights on the molecular level, homology models of PpADI WT and its 
variants were generated using YASARA Structure Version 14.7.17 (www.yasara.org) (Krieger et 
al. 2002). The crystal structures of PaADI (PDB ID: 1RXX and 2A9G) were selected as templates 
for the modeling because PaADI exhibited 84.9% sequence identity 
(http://blast.ncbi.nlm.nih.gov/Blast) with PpADI. The models of the apoPpADI (in the absence of 
substrate) and holoPpADI (in the presence of substrate) were built based on the crystal 
structures of the apoPaADI (1RXX) and holoPaADI (2A9G, PaADI in complex with L-arginine), 
respectively. 
Each homology model was neutralized and solvated in a periodic box containing TIP3P water 
(Miyamoto and Kollman 1992) and 0.9% NaCl. All simulations were performed using AMBER99 
force field (Duan et al. 2003) implemented in YASARA. Electrostatics were calculated using a 
cutoff of 7.86 Å, long range interactions were calculated using particle-mesh Ewald integration 
(Krieger et al. 2003). Bond length to hydrogens and bond angles in water were constrained to 
speed up the simulation. After initial minimization by steepest descent and simulated annealing 
until convergence (<0.02 kJ/mol per atom during 200 steps) reached, 3 runs of 10 ns molecular 
dynamic simulation at 310 K, pH 7.4 and a solvent density of 0.997 g/L (Krieger et al. 2004) was 
performed for each simulation setup. Snapshots were taken every 25 ps and the last 5 ns 
trajectories were statistically analyzed using YASARA and VMD1.9 (Krieger et al. 2003). 
4.2.2. Generation of the ’loop library’ and screening by LiMEx screening system (screening) 
and ADS (rescreening) 
The loop1 and loop4 mutagenesis libraries based on PpADI M6 at amino acid positions 37, 38, 
42, 43, and 402, 403, 404 were generated as previously described in 2.3.5.1. The PCR protocol 
and primers used for mutagenesis are shown in Table 11 and Table 23, respectively. The 
resulting PCR product was purified using a PCR purification kit (Macherey-Nagel, Düren, 
Germany), then digested with DpnI and transformed into NEB 5-alpha electrocompetent E. coli 
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cells (New England Biolabs, Frankfurt, Germany) and cells were spread onto LBkan agar plates 
(transformation efficiency > 109 CFU/mL). On the next day, the plasmids were isolated from the 
colonies and transformed into E. coli BL21-Gold (DE3)/pArg-LiMEx (prepared as described in 
section 2.3.5.1). 
Table 23. PCR primers used for loop-saturation mutagenesis. Saturated nucleotides are underlined. 
Name Sequences (5’-3’) 
Loop1_SSM37384243_fwd ACC CCG AGC AAC NNK NNK GAG CTG CTG NNK NNK GAA GTG ATC TGG GTC GAC CAG 
Loop1_SSM37384243_fwd CCA GAT CAC TTC MNN MNN CAG CAG CTC MNN MNN GTT GCT CGG GGT CAG GCG CTT G 
Loop4_SSM402403404_fwd CGA ACT GGG CCG GGG CCG TGG CNN KNN KNN KTG CAT GAC CTG CCC GAT CG 
Loop4_SSM402403404_rev GAC CAC GCT GGC ACC TTC GCT CCC CGG CAG GTC CTG 
 
BD Influx cell sorter (BD Biosciences, San Jose, CA) was used for sorting (main screening step) as 
described in the section 3.3.4. During sorting, single cells were spotted onto LBkan/cm agar plates 
and then incubated (37 °C for 12-14 h) until colonies formed. ADS screening system was 
employed as a rescreening method. Cell lysate (20 µL) of E. coli BL21-Gold (DE3)/pArg-
LiMEx/pET42-PpADI was transferred into 96-well MTPs (flat bottom, transparent) which were 
supplemented with 80 µL assay reagent (0.4 mM NADH, 5 mM α-ketoglutarate, and 5.55 U 
GDH) into each well, and the assay plates were incubated at 37 °C for 5 minutes. The cascade 
reaction was initiated by the addition of 100 µL arginine solution (0.1 mM, pH 7.4, PBS buffer) 
and the absorbance at 340 nm was recorded using a microtiter plate reader (Tecan Sunrise, 
Tecan Group AG, Zürich, Switzerland). The Beer-Lambert law was used for calculating the 
ammonia production velocity (v∆c) as previously described in section 2.3.5.1. 
4.2.3. Site-directed mutagenesis and site-saturation mutagenesis for recombination of 
selected amino acid positions 
Site-directed and site-saturation mutagenesis of the PpADI at amino acid positions 400, 354, 
136, 163, 193, 215, 288, and 312 were performed as previously described in section 2.3.5.2. 
Variants with recombined substitutions were generated using PpADI M6 or M31 as templates 
and the primers are listed in Table 24. The resulting PCR product was purified by using a PCR 
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purification kit (Macherey-Nagel, Düren, Germany) then digested with DpnI and transformed 
into E. coli BL21-Gold (DE3). 
Table 24. PCR primers used for site-directed mutagenesis. Substituted nucleotides are underlined. 
Name Sequences (5’-3’) 
R400M_fwd GAA CTG GGC CGG GGC ATG GGC GGC GGC CGT TGC 
R400M_rev GCA ACG GCC GCC GCC CAT GCC CCG GCC CAG TTC 
R400_fwd GAA CTG GGC CGG GGC NDT GGC GGC GGC CGT TGC 
R400_rev GCA ACG GCC GCC GCC AHD GCC CCG GCC CAG TTC 
D43S_M6fwd CAC GAG CTG CTG TTC TCC GAA GTG ATC TGG GTC 
D43S_M6rev GAC CCA GAT CAC TTC GGA GAA CAG CAG CTC GTG 
A275N_M6fwd CTG CCG AAG TCC CGT AAC GCG ATG CAC CTG GAC 
A275N _M6rev GTC CAG GTG CAT CGC GTT ACG GGA CTT CGG CAG 
D43S_M31fwd CAC GGG CTG CTG TAC AGC GAA GTG ATC TGG GTC 
D43S_M31rev GAC CCA GAT CAC TTC G CT GTA CAG CAG CCC GTG 
D43_M31fwd CAC GGG CTG CTG TAC NNK GAA GTG ATC TGG GTC 
D43_M31rev GAC CCA GAT CAC TTC MNN GTA CAG CAG CCC GTG 
A275_M31fwd CTG CCG AAG TCC CGT NNK GCC ATG CAC CTG GAC 
A275_M31rev GTC CAG GTG CAT GGC MNN ACG GGA CTT CGG CAG 
W354_M31fwd GCC GAG CGC GAG CAG NNK GAT GAC GGC AAC AAC 
W354_M31rev GTT GTT GCC GTC ATC MNN CTG CTC GCG CTC GGC 
 
4.2.4. Expression and purification of PpADI variants 
PpADI variants were expressed in shaking flasks. Protein concentrations after the final 
purification step were measured using the Thermo Scientific Pierce BCA protein assay kit 
(Rockford, IL, USA). 
4.2.5. Calculation of kinetic data of PpADI variants 
The experimental procedures for S0.5 (‘KM’) and Kcat determination using ammonia detection 
assay were performed as previously described in the section 2.3.7.  
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4.3. Results  
4.3.1. Computational analysis of possible structural changes of WT and M6 for the KM 
difference 
The structural models of the apoPpADI and holoPpADI WT and variants were built by homology 
modelling (details see section 4.2.1) based on the structures of apoPaADI (1RXX) (Galkin et al. 
2004) and holoPaADI (2A9G) (Galkin et al. 2005), respectively. Comparison of the active site of 
apoPpADI M6 and holoPpADI M6 showed that in the absence of substrate, the Arg400 side 
chain points into the active site and its orientation is stabilized through ion pair interaction with 
the carboxylate group of Asp166 (Figure. 28a). When the substrate L-arginine enters the binding 
pocket, it displaces the Arg400 side chain to form an enzyme-substrate complex. Upon the 
substrate binding, the guanidinium group of Arg243 shifts by ~5 Å to form an electrostatic 
interaction with carboxylate group of the L-arginine substrate, and the Arg400 side chain 
interacts with loop1 (a salt bridge was built between Arg400 and Asp43) at the entrance of the 
active site (Figure 28b). 
 
Figure 28. Protein structures of apo (a) and holo (b) PpADI M6. Important residues are highlighted in sticks. Loop1 and loop4 are 
colored in green and red, respectively. The H-bond between D43 and R400 is highlighted in yellow color. 
In order to understand how structural changes modulate different KM values of WT and M6 
variant, molecular dynamics (MD) simulations of PpADI WT and M6 (both in apo and holo 
forms) were performed as described in section 4.2.1. The obtained trajectories from MD 
simulation studies were analyzed by YASARA Structure and VMD. RMSD (root mean square 
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deviation) and RMSF (root mean square fluctuation) values are two parameters that can 
indicate changes in the orientation of the studied amino acid residues. The RMSD and RMSF 
analyses show a general increase in RMSD and RMSF of the residues in loop4 (the closest loop 
to the substrate binding site) of M6 variant compared to WT. Among the residues forming 
loop4, Arg400 of M6 variant demonstrated the most significant increase in RMSD (from 0.34 to 
0.44 Å, Table 25) and RMSF (from 1.07 to 1.30 Å, Table 26). Figure 29 shows the conformation 
changes of several important residues close to the substrate by comparison of the first and last 
snapshot of the MD simulation. After 10 ns MD simulation, R400 in M6 moves further away 
from H38 in contrast to WT (Figure 29). Based on these simulation results, it can be 
hypothesized that the apparent competition between the substrate and the Arg400 side chain 
for Asp166 may reduce the affinity of the PpADI for its substrate. Consequently, the more 
flexible of the side chain of R400 (increased RMSD and RMSF values) is, the less efficient would 
be the blocking of the active site, which in turn can explain the observed decreased KM values. 
Table 25. Average RMSD values of Arg400 calculated from the last 5 ns simulation time using YASARA. The RMSF values were 
calculated for all residue atoms. STDEV (standard deviation) values are shown in the brackets. 
Variant  RMSD ofArg 
400 in chain 
A (Å) 
RMSD ofArg 
400 in chain B 
(Å) 
RMSD of 
Arg400 in 
chain C (Å) 
RMSD of 
Arg400 in 
chain D (Å) 
Overall RMSD 
of Arg400 (Å) 
S0.5  
(mM) 
WT_holo 0.32/ 
(0.02) 
0.37/ 
(0.05) 
0.31/ 
(0.05) 
0.39/  
(0.12) 
0.34/ 
(0.06) 
1.31 
M6_holo 0.38/ 
(0.14) 
0.38/ 
(0.10) 
0.52/ 
(0.17) 
0.48/  
(0.12) 
0.44/ 
(0.13) 
0.81 
 
Table 26. Average RMSF of Arg400 calculated from the last 5 ns simulation time using YASARA. The RMSF values were calculated 
for all residue atoms. STDEV (standard deviation) values are shown in the brackets. 
 RMSF of 
Arg400 in 
chain A (Å) 
RMSF of 
Arg400 in 
chain B (Å) 
RMSF of 
Arg400 in 
chain C (Å) 
RMSF of 
Arg400 in 
chain D (Å) 
Overall RMSF 
of Arg400 (Å) 
S0.5 
 (mM) 
WT_holo 0.91/ 
(0.18) 
1.18/ 
(0.33) 
1.13/ 
(0.44) 
1.08/  
(0.37) 
1.07/ 
(0.31) 
1.31 
M6_holo 1.18/ 
(0.50) 
1.56/ 
(0.13) 
1.17/ 
(0.41) 
1.30/  
(0.27) 
1.30/ 
(0.34) 
0.81 
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Figure 29. Snapshots of structure of PpADIs, i.e. 0 ns holo forms of PpADI WT and M6, and 10 ns holo forms of PpADI WT and 
M6. The selected residues are shown in sticks. 
4.3.2. Loop1 and loop4 PpADI mutagenesis library generation and screening by Arg-LiMEx 
and ADS 
Based on the computational analysis in section 4.3.1, the substitution R400M was introduced 
into WT and M6, since MaADI (KM = 4 µM) contains a Met, not Arg, at the corresponding 
position. Unfortunately, both variants (WT+R400M and M6+R400M) were found to be inactive 
towards L-arginine. Furthermore, none of the variants from a SSM library (NDT codon) of R400 
showed deiminase activity indicating that arginine at the position 400 is indispensable in PpADI 
WT and M6. As a next step, in order to further reduce the KM values of PpADI, four amino acid 
positions forming loop1 (37, 38, 42, 43) and three positions in loop 4 (402, 403, 404) were 
selected for mutagenesis, because they are in close proximity to position R400 (see Figure 30). 
The loop1 library simultaneously saturated positions 37, 38, 42, and 43 (NNK codon for each 
position, library size = ~3.1×106 variants) and loop4 library simultaneously saturated positions 
402, 403 and 404 (NNK codon for the three positions, library size = ~9.8×104 variants). 
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Figure 30. Protein structure of holo form PpADI M6. The selected residues and substrate are shown in sticks. The H-bond 
between D43 and R400 is highlighted in yellow color. 
For the engineering of loop1, PpADI M6 was employed as a parent; the newly developed Arg-
LiMEx (beads on flow cytometry, throughput > 107, see section 3.3.4) and ADS screening 
systems (in MTP format, throughput = ~104, section see 2.3.1) were used as screening and 
rescreening methods, respectively. The variants that fell in the 1% highest fluorescence signal in 
flow cytometer were collected and spotted on the agar plates (Figure 31); such stringent 
conditions were applied because > 90% clones are inactive from initial MTP test. The 
rescreening results using ammonia detection assay showed that PpADI activity was detected in 
~90% of sorted cells, and ~10% of the sorted cells showed a >1.5-fold improvement compared 
to the parent M6 on the MTP (0.1 mM arginine as substrate). Finally, four PpADI variants were 
selected because of their higher activities and lower S0.5 values as compared to M6 (Table 27). 
The three variants with the ‘lowest’ S0.5 values harbored substitutions/mutations at position 37 
(M6-L1-1: C37T, 0.56 mM; M6-L1-2: C37K, 0.69 mM; M6-L1-3: C37A, 0.48 mM), which suggested 
that this position is crucial for improving substrate’s affinity of PpADI. Interestingly, one 
positively charged residue invariably occurred at position 37 or 38 in all the four beneficial 
variants (M6-L1-1: K38; M6-L1-2: K37; M6-L1-3: H38, M6-L1-4: H38), which indicated that a 
positive charge is necessary at this area. Furthermore, loop4 engineering was performed in a 
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similar manner as loop1 engineering, but no variant with significantly decreased S0.5 value was 
found in the respective library. 
 
 
Figure 31. Flow cytometer sorting of the loop1 library (PpADI M6 as parent). The sorting gate P1 (< top 1% of fluorescent 
population) is shown in (a), and positive control (no ArgR expression) are negative control (EV, no ADI expression) are shown in 
(b).  
 
Table 27. Apparent kinetic constants (S0.5 values and v∆c,app) and substitution of improved PpADI variants from these loop 
libraries (Experiments were performed with crude cell extracts.) 
Variants Substitutions S0.5,app  
(mM) 
v∆c,app (μM·s
-1
)* 
[Arginine] =100 μM 
M6 (parent) - 0.81 0.032 
Loop1_1 C37T, H38K, F42Y 0.56 0.061 
Loop1_2 C37K, H38I 0.69 0.051 
Loop1_3 F42Y 0.79 0.039 
Loop1_4 C37A 0.48 0.095 
 
Chapter IV: Loop engineering of PpADI revealed the importance of 
loop1, loop4 and Arg400 in modulating substrate affinity 
 Page 76 
 
4.3.3. Sequence and structure comparison of ADIs within 6 Å from position 400  
The results in 4.3.2 (no improved variants were found from the SSM library of R400) indicated 
that Arg at the position 400 seems indispensable for activity. However, alignment of amino acid 
sequences of two ADIs (MaADI and MpADI) with low KM values (< 10 µM) showed a Met at the 
corresponding position. Therefore, a detailed comparison of the sequence alignment of ADIs 
with low and high KM values was performed in an attempt to identify correlated amino acid 
differences giving the reasons for this discrepancy. Five well-studied ADIs were selected, i.e. 
MaADI, MpADI and BcADI, PaADI, and PpADI (Li et al. 2008). The MaADI and MpADI have lower 
KM values- 4 µM and 10 µM, whereas the KM values for BcADI, PaADI and PpADI M6 are higher, 
90 µM, 140 µM and 810 µM, respectively (Li et al. 2008). Figure 32a shows the sequence 
comparison of all the residues, in these five ADIs, within a distance of 6 Å from position 400 (e.g. 
there are three regions of MaADI in this area: from amino acid position L42 to L48, V260 to 
L269, and E337 to N344). Interestingly, it was observed that at position 43, the ADIs with lower 
KM values contain a Ser, while aspartic acid is found at this position of PaADI and PpADI M6 with 
higher KM values. Similarly, at positions 275 and 354, ADIs with lower KM values (MaADI and 
MpADI) have the same residues i.e. Asn and His, respectively. ADIs with higher KM values (BcADI, 
PaADI and PpADI) harbor Ala and Trp at positions 275 and 354. The Figure 32b represents the 
structure comparison of a lower KM value ADI (MaADI) and a higher KM value ADI (PpADI), which 
shows that the residues at these three positions surround residue 400. All four residues build a 
micro environment that affects substrate (arginine) pass in and out of the binding site. 
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Figure 32. Sequence and structure comparison of ADIs. (a) Multiple sequence alignment of MaADI, MpADI and BcADI, PaADI, 
and PpADI (b) Structure alignment of MaADI (green color in main chain) and PpADI M6 (red color in main chain), The selected 
residues are highlighted in sticks. 
4.3.4. Rational reengineering of PpADI 
MD simulation analysis revealed the important role of position 400 (section 4.3.1), and the 
sequence and structure comparison of ADIs indicated that three positions (43, 275, 347) might 
be important for reducing the KM value of PpADI together with the substitution of R400M. 
Therefore, several variants of M6 were generated by SDM for substituting these positions and 
the apparent kinetic constants were determined by using ammonia detection system (Table 28). 
The variants M6+R400M, M6+W354H, M6+W354H+R400M, M6+W354H+R400M+A275N, and 
M6+W354H+R400M+A275N+D43S did not show any activity towards arginine. These suggested 
that substitutions R400M and W354H are unfavorable for PpADI activity. Further, M6+D43S 
displayed similar KM value as compared with M6. Interestingly, variant M6+R400M+D43S 
showed deiminase activity. The KM value of M6+R400M+D43S was dramatically decreased from 
~0.79 mM (M6) to ~0.17 mM, however the activity at 100 µM arginine also decreased from 
0.030 μM·s-1 to 0.022 μM·s-1. Substitution A275N did not influence the kinetic performance of 
M6+R400M+D43S. Taken together, the substitutions R400M and D43S mediated cooperative 
effects on kinetic parameters of PpADI towards L-arginine.  
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Table 28. Apparent kinetic constants (S0.5 values and Kcat) of PpADI variants (Experiments were performed with crude cell 
extracts.) 
ND: not detectable 
Because of the success of reducing S0.5 value of M6 (~0.8 mM of M6 to 0.17 mM of 
M6+R400M+D43S), a variant M31+R400M+D43S was generated by introducing R400M and 
D43S on M31 (a high activity variant, identified in section 3.4.6). However, the S0.5 value showed 
only a slight decrease from 0.17 mM to 0.15 mM (Table 29). Furthermore, D43S alone did not 
influence the KM value compared with M6 (see PpADI L8 in Table 28). The possible reason is that 
the substitution D43S might not be the ‘best’ recombination together with Met at position 400. 
Therefore, three site-saturation mutagenesis libraries at positions W354, A275 and D43 were 
generated using PpADI L9 as the template and screened. 
Table 29. Apparent kinetic constants (S0.5 values and Kcat) of PpADI variants (Experiments were performed with crude cell 
extracts.) 
ND: not detectable 
Variants S0.5 app 
(mM) 
v∆c,app (μM·s
-1
) 
 [Arginine] =100 μM 
M6 0.79 0.030 
L1 (M6 + R400M) - ND 
L2 (M6 + W354H+ R400M) - ND 
L3 (M6 + W354H+ R400M+A275N) - ND 
L4 (M6 + W354H+ R400M+A275N+D43S) - ND 
L5 (M6 + W354H) - ND 
L6 (M6 + R400M+D43S) 0.17 0.022 
L7 (M6 + R400M+D43S+A275N) 0.15 0.023  
L8 (M6 + D43S) 0.76 0.019  
Variants S0.5 ,app 
(mM) 
v∆c,app (μM·s
-1
) 
 [Arginine] =100 μM 
M31 0.19 mM 0.083 
L9 (M31 + R400M) - ND 
L10 (M31 + R400M + D43S) 0.17 mM 0.033 
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4.3.5. Site-saturation mutagenesis of positions W354, A275 and D43 on PpADI M31+R400M  
Three site-saturation mutagenesis libraries at W354, A275 and D43 on PpADI M31+R400M were 
generated according to a published method (Wang and Malcolm 1999). After screening 93 
clones of each library, no active variants were found from the first two libraries (W354, A275) 
on M31+R400M. Six out of 96 variants showed activity from the library D43 on M31+R400M. 
Among these six variants, four variants displayed similar activity as PpADI L10 
(M31+R400M+D43S), and others displayed lower activity compared to PpADI L10. All these 6 
active variants and 3 inactive variants were sequenced. The results revealed a substitution to 
Ser or Thr at the position 43 led to similar activity as PpADI L10 (~0.032 μM·s-1 at [arginine] = 
100 μM, see Table 29), which indicated that a small polar residue is preferred when position 
400 harbors a Met. Arg, Phe, Ala and Leu were identified at position 43 of four inactive variants 
(Table 30), respectively, suggesting that positively charged, small and non-polar, and bulky and 
non-polar amino acids are not preferred at this position. 
Table 30. Apparent kinetic constants (S0.5 values and Kcat) of PpADI variants from the library D43 on PpADI M31+R400M 
(Experiments were performed with crude cell extracts.) 
ND: not detectable 
4.4. Discussion 
In this section, loop engineering and MD simulations were performed to study the structure-
function relationship of identified beneficial positions and the gating residue 400 for reducing 
Variants S0.5 app 
(mM) 
v∆c,app (μM·s
-1
) 
 [Arginine] =100 μM 
M31 0.19 0.083 
M31 + R400M - ND 
M31 + R400M + D43S 0.17 0.033  
M31 + R400M + D43T 0.15 0.031 
M31 + R400M + D43A - ND 
M31 + R400M + D43L - ND 
M31 + R400M + D43R - ND 
M31 + R400M + D43F - ND 
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the S0.5 value of PpADI. Position 400 located in loop 4 was identified to play an important role 
for the substrate’s affinity of PpADI which is attributable to its local flexibility (RMSF and RMSD). 
The sequence/structure alignment with ADIs harboring low KM values identified several 
potentially beneficial positions for lowering S0.5 values. Based on these analyses, three rational 
libraries were designed and screened. Variants L6 (M6+R400M+D43S) and L10 
(M31+R400M+D43S) exhibited lower S0.5 values (0.19 mM and 0.17 mM) compared to M6 
(~0.80 mM). Furthermore, we found that when Arg was replaced by Met at position 400, a small 
polar residue (Ser or Thr), instead of Charged Asp, was preferred at the structurally neighboring 
position 43 in loop 1 (see Figure 32b) in order to maintain the active site environment and 
PpADI’s activity. 
A hypothesis, high flexibility of the side chain of gating position 400 is beneficial for arginine 
conversion at low substrate concentration, was proposed after studying possible structurally 
dynamic changes of the residues on loop1 and loop4 in PpADI WT and M6. Position 400 had 
increased flexibility (RMSF and RMSD values) in the PpADI variant M6 (S0.5 = ~0.8 mM; RMSD400 = 
0.44, RMSF400 = 1.30) which has a lower S0.5 value compared to WT (S0.5 = ~1.3 mM; RMSD400 = 
0.34, RMSF400 = 1.04). These findings prompted us to generate a loop1 library (saturation 
mutagenesis at positions 37, 38, 42 and 43) and a loop4 library (saturation mutagenesis at 
positions 402, 403 and 404). After screening of these two libraries, three variants with the lower 
S0.5 values was identified (PpADI loop1_1: 0.56 mM; PpADI loop1_2: 0.69 mM; PpADI loop1_3: 
0.48 mM) compared to PpADI M6. However, no improved variants could be obtained from the 
loop 4 library screening. Furthermore, two variants PpADI L6 (M6+R400M+D43S) and PpADI L10 
(M31+R400M+D43S), harboring very low S0.5 values (L6: 0.19 mM and L10: 0.17 mM) were 
identified from rationally designed libraries with combined loop1 and loop4 mutations. In order 
to investigate the role of M400, the RMSD and RMSF of M400 in MD simulations of PpADI L6 
were analyzed. As expected, the RMSD of M400 increased from 0.44 (PpADI M6) to 0.62 (PpADI 
L6), and RMSF increased from 1.30 (PpADI M6) to 1.66 (PpADI L6) (Table 31 and Table 32). This 
strongly supports the hypothesis that the more flexible of the side chain of the residue at 
position 400, the lower the S0.5 value of PpADI is. 
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Table 31. Average RMSD of residue 400 calculated across the last 5 ns simulation time. The RMSD values were calculated for all 
residue atoms. STDEV (standard deviation) values are shown in the brackets. 
Variant  RMSD of 400 
at chain A (Å) 
RMSD of 400 
at chain B (Å) 
RMSD of 400 
at chain C (Å) 
RMSD of 400 
at chain D (Å) 
Overall RMSD 
of 400 (Å) 
S0.5  
(mM) 
WT_holo 0.32/ 
(0.02) 
0.37/ 
(0.05) 
0.31/ 
(0.05) 
0.39/  
(0.12) 
0.34/ 
(0.06) 
1.31 
M6_holo 0.38/ 
(0.14) 
0.38/ 
(0.10) 
0.52/ 
(0.17) 
0.48/  
(0.12) 
0.44/ 
(0.13) 
0.81 
M6+R400M+D43S_holo 0.59/ 
(0.12) 
0.41/ 
(0.12) 
0.64/ 
(0.10) 
0.82/  
(0.08) 
0.62/ 
(0.17) 
0.19 
 
Table 32. Average RMSF of residue 400 calculated across the last 5 ns simulation time. The RMSF values were calculated for all 
residue atoms. STDEV (standard deviation) values are shown in the brackets. 
 
Although the S0.5 values decreased from 1.31 mM of WT and 0.81 mM of M6 to the 0.19 mM of 
PpADI L6, the activity of PpADI L6 was slightly reduced to 0.022 μM·s-1 (towards 100 µM L-
arginine) when compared to PpADI M6 (from 0.030 μM·s-1) (Table 28). The possible reason is 
that substitutions R400M and D43S form a weak H-bond (see Figure 30, whereas R400 was 
involved in a salt bridge with residue D43 in WT and M6 near the substrate binding site) and the 
salt bridge may be beneficial for arginine conversion into citrulline. Due to the decreased 
activity and increased substrate affinity from PpADI M6 to L6, we performed site-saturation 
mutagenesis at position 43 (+R400M) using a highly active variant PpADI M31 as parent. In this 
variant PpADI L9 (M31+R400M), the substitutions at position 43 from Asp to Ser or Thr led to 
have similar activities at [arginine] = 100 μM (Table 30). Arg, Phe, Ala and Leu were identified at 
position 43 in low active or inactive variants (Table 30). This might be due to the reason that a 
positively charged (e.g. Arg) or small and non-polar (e.g. Leu) residues would change the loop 
conformation by rearrangement of the H-bond network, or bulky and non-polar residues (such 
as Phe) may interfere with Met at position 400. Therefore, it is can be explained why small polar 
residues (Ser and Thr) are preferred for PpADI’s activity when Met is at the position 400. 
 RMSF of 400 
at chain A 
RMSF of 400 
at chain B 
RMSF of 400 
at chain C 
RMSF of 400 
at chain D 
Overall RMSF 
of 400  
S0.5 (mM) 
WT_holo 0.91/ 
(0.18) 
1.18/ 
(0.33) 
1.13/ 
(0.44) 
1.08/  
(0.37) 
1.07/ 
(0.31) 
1.31 
M6_holo 1.18/ 
(0.50) 
1.56/ 
(0.13) 
1.17/ 
(0.41) 
1.30/  
(0.27) 
1.30/ 
(0.34) 
0.81 
M6+R400M+D43S_holo 1.61/ 
(0.04) 
1.52/ 
(0.12) 
1.89/ 
(0.28) 
1.64/  
(0.07) 
1.66/ 
(0.20) 
0.19 
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However, the measured activity of PpADI L10 (non-purified protein, towards 100 µM arginine) 
decreased from 0.083 mM μM·s-1 (M31) to 0.033 μM·s-1 (Table 30).  
Furthermore, MD simulations were employed to study the structure-function relationship. The 
role of loop flexibility on PpADI’s substrate affinity was highlighted by the above analysis of 
compared experiments data with the MD simulations data. Recent advances have also 
emphasized the important role of the flexibility of loops on enzyme activity (Bhabha et al. 2011), 
enzyme substrate specificity (Giger et al. 2013) and protein stability (Wintrode et al. 2003). For 
example, Goddard group carried out simulations on the para-nitrobenzyl esterase and two 
thermostable variants generated by laboratory evolution to study how protein structure and 
dynamics are affected by adaption to high temperature (Wintrode et al. 2003). The results 
revealed that the most dramatic changes between the thermophilic mutant 8G8 and WT were 
in the regions composed of residues 315−323 undergoing fluctuations of up to 6 Å in 8G8, while 
they showed little movement in WT.  
4.5. Conclusions 
In conclusion, amino acid position 400 was identified, by experiments and MD simulations data, 
to play an important role for the substrate affinity in PpADI (S0.5 value) which is attributable to 
its flexibility. A hypothesis was then proposed that the high flexibility of the side chain of gating 
position 400 (increased RMSD and RMSF values) is beneficial for arginine conversion at low 
concentration. Two loop saturation mutagenesis libraries (positions closed to R400 were 
selected) and three rationally designed libraries were screened. Several variants with lower S0.5 
value (compared to PpADI M6) were obtained. Furthermore, site directed mutagenesis at both 
positions 400 and 43 simultaneously led to variants with significantly reduced S0.5 values 
compared to M6 and M31. The SSM library at position 43 showed that small polar residues (Ser 
and Thr) are preferred at this position when methionine is at position 400 to get a low S0.5 value. 
Taken together, we conclude that engineering of flexible loops associated with enzyme 
functions has many opportunities for obtaining the enzyme variants with desired properties. 
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5. Chapter V: Surface engineering of PpADI for efficient PEGylation 
5.1. Introduction 
In recent years, PEGylation (the process of covalent attachment or amalgamation of 
polyethylene glycol (PEG) polymer chains to macrostructures) has emerged as a dominant 
strategy for improving drug solubility, decreasing of dosage frequency, and increasing of drug 
stability (Xu and Anchordoquy 2011). For example, recombinant human arginase I (rhArgI) was 
successfully cloned and expressed in E. coli. However, the unacceptably short circulatory half-
life of native arginase in the human body (t1/2 <30 min) makes it difficult to maintain a 
therapeutically effective (low) blood arginine concentration in patients. Sam-Mui Tsui et. al., 
coupled rhArgI with mPEG-SPA 5,000. The resulting PEGylated rhArgI had up to 6 PEG chains of 
5 KD which protected it from degradation and any residual immunogenicity. After a single 
injection of 1,500 U of the PEGylated enzyme, plasma arginine decreased to >0.05 μM from 
~170 μM within 20 min and lasting 6 days. Up to now, at least nine PEGylated protein drugs are 
on the market (Alconcel et al. 2011), including Adagen®, Oncaspar®, and Krystexxa® (Reddy 
2000). 
The main PEGylation approaches include random PEGylation and site-specific PEGylation. In 
regard to increasing regulative requirements in modern pharmaceutical production by means of 
reproducibility and product consistency, site-specific PEGylation is of growing interest. Proteins 
with specific sites are firstly purified and then PEG attach to the specific sites. Approaches for 
specific modification include, for example, enzymatic techniques such as glycoPEGylation and 
transglutaminase mediated modification or an attachment via introduced binding sites (Sergi et 
al. 2009). However, such techniques are non-trivial and demand for a time consuming 
development. In addition, all site-specific PEGylation approaches are still in development or 
clinical phase, and a fast FDA approval especially for genetically introduced binding sites might 
be problematic (Maiser et al. 2014). 
In contrast to the site specific approach, random PEGylation reactions (reacts with the Ɛ-amino 
side chains of lysine or the N-terminal α-amino group) were successfully used in most instances 
of already approved PEGylated products, such as PEGylated interferon and epoetin (Maiser et al. 
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2014). Lysine residues are generally well represented in proteins. However, many of them are 
buried in the protein where PEG molecules could not be attached, which decreased the 
PEGylation efficiency. Therefore, to increase the PEGylation efficiency, it is necessary to 
introduce more lysine residues on the surface of proteins, e.g., by replacing non-essential (not 
reduce the enzyme activity) arginine with lysine. 
In the previous chapters (II – III), a PpADI variant M31 exhibiting significantly improved activity 
was obtained after several rounds of directed evolution campaigns. The in vitro tumor cell line 
tests showed that M31 displayed the lowest IC50 value against the SK-MEL-28 (0.02 µg/mL; 0.24% 
of WT) and G361 (0.02 µg/mL; 0.45% of WT) cell lines. In this chapter, surface engineering of 
M31 to introduce more lysines for efficient PEGylation was performed to improve its half-life in 
PBS buffer and serum. Firstly, an optimized protocol for PEGylation and purification method for 
PEGylated PpADI was developed; secondly, a in silico strategy for selection of potential Arg 
positions to be replaced by Lys for PEGylation was developed with three steps: 1) selection of 
Arg positions which have accessible surface area > 90 Å2, 2) selection of Arg positions which 
have ∆∆GFoldX (Changes in free energy) < 2 kcal/mol when mutated to Lys, 3) after replacing Arg 
with Lys, selection of the positions showing the predicted pKa value lower than the reference 
pKa (10.76 of Lys in YASARA software). Based on this three-step strategy, four positions were 
selected and five variants were then generated. Finally, the thermal resistant of the PEGylated 
PpADI variants and non-PEGylated PpADI variants were determined both in the PBS buffer and 
human serum. 
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5.2. Materials and Methods 
Activated PEG reagents were purchased from JenKem Technology USA Inc. (Plano, TX, USA). 
HiPrep Q FF column was supplied by GE Healthcare (NJ, USA). The information of other chemical 
reagents was stated in the sections above (2.3. and 3.3). The solution for Bradford Protein Assay 
was from Bio-Rad Laboratories, Inc. (Munich, Germany). 
5.2.1. Homology modeling 
A homology model of PpADI M21 was generated as described in the section 4.3.1. The 
additional substitutions (from M21 to M31) were introduced simultaneously on the model of 
PpADI M21 by using the YASARA FoldX-plugin. Later, the variants harboring single mutation 
compared to PpADI M31 were built using the “mutate (multiple) residue” command. 
5.2.2. The analysis of the relative changes in folding free energy (∆∆GFoldX)  
The relative changes in free energy ∆∆GFoldX due to point mutations and the 3D structures of the 
corresponding mutant enzymes were predicted with FoldX (version 3.0 beta3, foldx.crg.es) on 
the basis of the homology model PpADI M19. The predicted ∆∆GFoldX equals to the ∆GFoldX for 
the protein carrying the point mutation minus the ∆GFoldX for the WT protein. The standard 
settings of the software, which had been optimized on a large test set, were used. Temperature, 
pH, and ionic strength were assigned as 298 K, 8.0, and 0.05 M, respectively and the calculations 
were repeated five times to obtain a better average. 
5.2.3. Solvent-accessible surface area (SASA) of each residue on PpADI 
Solvent-accessible surface area (SASA) of a certain residue was calculated by YASARA software 
with the 'Surf' command. 
5.2.4. Site-directed mutagenesis for introducing substitutions R299K, R319K, R338K, and 
R382K on PpADI M31 
Site-directed mutagenesis of the PpADI M31 at amino acid positions 299, 319, 338 and 382 was 
performed as previously described in section 2.3.5.2. PpADI M31 was used as a template 
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(obtained from 3×epPCR and the following recombination, Part III) using primers outlined in 
Table 33. The resulting PCR product was purified using a PCR purification kit then digested with 
DpnI and transformed into E. coli BL21-Gold (DE3). 
5.2.5. Recombinant expression and purification of PpADI 
Recombinant expression of PpADI in E. coli BL21-Gold (DE3) was performed as described in the 
section 2.4.3. Cells were collected and re-suspended in 20 mM PBS buffer, pH 7.4, then 
disrupted with Constant Cell Disruption Systems (Constant Systems Limited, United Kingdom). 
Crude enzyme extracts were subjected to anion-exchange chromatography on a HiPrep Q FF 
column. ADI was eluted by a NaCl gradient in PBS buffer (20 mM, pH 7.4). The obtained ADI 
fraction was then concentrated by a 10 kDa Amicon Ultra-50 (Millipore, MA, USA), and 
subjected to PD-10 desalting column. All the purification processes were carried out on an ÄKTA 
purifier (GE Healthcare, NJ, USA). 
5.2.6. Structural integrity of non- PEGylated and PEGylated PpADI M31  
Circular dichroism (CD) was used to identify any significant changes in the secondary structure 
of PpADI after PEGylation. CD spectra (from 190 to 240 nm) were measured with an Olis CD 
Spectrophotometer model SDM 17 (On/Line Instrument Systems, Inc., Bogart, USA) under a 
constant nitrogen flow, with spectra recorded from 190-240 nm by using a 1 mm path-length 
cell and a bandwidth of 1 nm. Each spectrum shown is the average of three individual 
measurements. Raw collected CD data were converted into delta epsilon (∆Ɛ, molar circular 
dichroism). Purified non-PEGylated and PEGylated PpADI M31 subjected to CD measurement. 
Baseline measurements were determined in phosphate buffer (Na2HPO4 and NaH2PO4, 50 mM, 
pH 8.0) and subtracted from the experimental data. CD data were analyzed by using K2D3 
online serve (k2d3.ogic.ca) to derive the α-helix and β-strand contents, making it possible to 
detect significant structural changes in the PEGylated enzyme. 
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5.2.7. Enzyme activity and kinetic analysis of non-PEGylated and PEGylated PpADI 
The ammonia-detection system was employed for detection of the kinetic data of non-
PEGylated and PEGylated PpADI variants as described in section 2.3.1. The citrulline detection 
assay was used to determine PpADI activity as describe in the section 3.3.6. The arginine 
conversion by PpADI variants or PEG-PpADI variants (20 µL) was initiated by the addition of 
arginine solution (10 mM, pH 7.4, PBS buffer), and the mixture was incubated (2 min, 37 °C). 
Next, acid-ferric solution (60 µL) and diacetyl monoxime (DAM, 20 µL, 0.5 M) were added for 
citrulline detection. The reaction mixture was incubated for 30 min at 55 °C. Absorbance was 
measured at 490 nm using a MTP reader (Tecan Sunrise, Tecan Group AG, Zürich, Switzerland). 
5.2.8. PEGylation of ADI 
An ADI solution of 0.5 mg/mL was prepared in 50 mM PBS buffer, pH 7.4. PEG reagents were 
added into the ADI solution to a molar ratio of PEG to ADI of 100:1, 50:1 or 20:1. The PEGylation 
reaction was carried out for 3 h or 24 h at room temperature, with magnetic stirring by Thermo 
Scientific Cimarec i Poly 15 Multipoint Stirrers (Thermo Fisher scientific, Germany). The reaction 
mixture was washed 3 times repeatedly with PBS (20 mM, pH 7.4) through a 50 kDa Amicon 
Ultra-50 (Millipore, MA, USA) to remove free PEGs. When non-PEGylated ADI was detected on 
SDS-PAGE, the concentrated PEG-ADI was further purified by anion-exchange chromatography. 
5.2.9. Molecule weigh analysis of ADI and ADI-PEG 
The non-PEGylated ADI, PEGylated ADI (ADI-PEG), or PEGylation reaction mixtures were 
analyzed by ExperionTM automated gel electrophoresis system with Experion Pro260 Analysis kit 
(Bio-Rad). 
5.2.10. Quantification of non-PEGylated PpADI and PEGylated PpADI  
A Bradford Protein Assay was used to measure the concentrations of purified PpADIs, and 
PEGylated PpADIs. Firstly, 20 μL sample was added in 96 well plate, then 100 μL 1x protein assay 
dye (Bio-Rad) was mixed with the sample in each well carefully by pipette. Thereafter, the plate 
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was incubated at room temperature for ~5 min and absorbance at 595 nm was measured using 
an MTP reader (Tecan Group AG, Zürich, Switzerland). 
5.2.11. Thermal resistance profile of PEGylated parent M31 and variants 
Thermal profile of PEGylated PpADI M31 (parent) and variants were determined by measuring 
the residual activity after heat treatment. Purified PpADI M31 (parent) and variants M32 to M36 
in phosphate buffer (Na2HPO4 and NaH2PO4, 50 mM, pH 7.4), were incubated at a range of 
twelve temperatures from 37 to 60 °C for 4 h. Subsequently, the samples were assayed for 
residual activity. The Tm values were determined from the plots of relative inactivation [%] 
versus temperature [°C]. The Tm value is defined as the temperature at which 50% of the initial 
enzyme activity is lost after heat treatment. 
5.2.12. Long-term thermal resistance of parent M31 and improved variants at 37 °C 
Non-PEGylated and PEGylated PpADI M31 (parent) and variants in phosphate buffer (Na2HPO4 
and NaH2PO4, 50 mM, pH 8.0) were incubated at physiological temperature (37 °C). The residual 
activities were determined at regular time intervals for up to seven days by using the citrulline 
detection assay. Furthermore, the stability of ADI and PEG-ADIs in human serum (from human 
male AB plasma, USA origin, sterile-filtered, Sigma, Steinheim, Germany) was also evaluated.  
5.3. Results 
5.3.1. Optimization of the PEGylation process of PpADIs 
PpADI variants were expressed and purified as previously described in the section of 2.3.6. ~100 
mg of non-PEGylated PpADI M31 (>95% purity) was routinely obtained per liter of culture. 
PpADI M31 was used to optimize the random PEGylation reaction process. Its molecular weight 
is ~46 kDa (Figure 33a). 
The most frequently used derivatives for lysine attachments are the N-hydroxylsuccinimide 
(NHS) active esters, such as PEG succinimidyl succinate (mPEG-SS). Therefore, the mPEG-SS 
(Figure 33b) was used for the PEGlytion of PpADI in this study. Reaction between the Ɛ-amino 
group of lysine(s) or the N-terminal amine and the NHS ester produces a physiological stable 
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amide linkage(s) (Figure 33c). Generally, increasing pH increases the rate of reaction and 
lowering pH reduces rate of reaction. In this case, PEGlytion reactions were performed at 
physiological pH (7.4) and room temperature (~20 °C). To optimize the reaction time and the 
amount of mPEG-SS required for complete PEGylation of PpADI, the purified PpADI M31 was 
incubated with molar ratio of 1: 20, 1: 50, and 1: 100 mPEG-SS concentrations with two 
different incubation times (3 h and 24 h). The products of PEGylation of PpADI (Figure 33b) were 
analyzed by SDS-PAGE (Figure 33d), which showed that the MW of PpADI after PEGylation was 
increased compared to non-PEGylated PpADI. After PEGylation, a mixture of PEG-PpADI M31 
with varied molecular weights was obtained (smear on the SDS PAGE) due to the size 
distribution of PEG molecules. Less non-PEGylated PpADI M31 was observed from the molar 
ratio of 1: 100 and 1: 50 (ADI: mPEG-SS) than 1: 20 (Figure 33d). Furthermore, different reaction 
times of 3 h and 20 h did not influence the yield of PEGylation (Figure 33d, lane 1 compares to 
lane 2, lane 5 compares to lane 6). From these results, the optimum PpADI: PEG ratio (molar) 
and reaction duration were determined to be 1: 50 and 3 h, respectively. 
 
Figure 33. (a) Purified PpADI and the purity analysis by Experion automated gel electrophoresis system with Experion Pro260 
Analysis kit (Bio-Rad). The molecular weight of non-PEGylated PpADI M31 is ~ 46 KDa. (b) The structure of mPEG-SS and NHS 
linker is shown in the blue box; (c) The scheme of the PEGylation of mPEG-SS to PpADI, (d) The protein level after PEGylation. 
Lane1-2: molar ratio of PpADI : mPEG= 1: 50, Lane3-4: molar ratio of ADI : mPEG= 1: 20, Lane5-6: molar ratio of PpADI : mPEG= 
1: 100; Lane1, 3, 5: 3 h reaction time, : Lane2, 4, 6: 24 h reaction time. 
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Non-PEGylated PpADI M31 was still detectable on SDS-PAGE. Therefore, the solution of PpADI 
after PEGylation was concentrated (through a 50 kDa Amicon Ultra-50) and further purified by 
anion-exchange chromatography (HiTrap Q HP, GE Healthcare Life Sciences). PEG-ADI did not 
bind to the column due to the shielded charges by PEG molecues; thereby it was collected from 
the flow through (Figure 34a). The PEG-PpADI M31 and PpADI M31were analyzed by ExperionTM 
automated gel electrophoresis system with Experion Pro260 Analysis kit. PEGylated PpADI M31 
was well purified from the mixture by anion-exchange chromatography, because there was no 
non-PEGylated PpADI observed (see Figure 34b, lane 1) from the sample of purified PEGylated 
PpADI M31. 
 
Figure 34. Separation of PpADI M31 and PEG-PpADI M31 from mixtures after PEGylation. Separation was performed by Ion 
exchange chromatography (a) and two fragments (after separation) were analyzed by Experion
TM
 automated gel electrophoresis 
system (b) with Experion Pro260 Analysis kit. 
5.3.2. CD spectroscopic analysis 
The secondary structures of PEGylated PpADI compared to non-PEGylated PpADI were 
evaluated by CD spectroscopy in the far-UV region of the spectra covering the wavelength range 
190-240 nm. A summary of the CD data with regard to the secondary structural compositions of 
ADI and ADI-PEG 20,000 Mw (Table 33) strongly suggested that the PEGylated PpADI M31 has 
no significant difference in secondary structure compared to non-PEGylated PpADI M31, since 
the percentage composition of each secondary elements (α helix and β strand) only varied by a 
maximum of 1% between the non-PEGylated and PEGylated PpADI (Table 33, predicated by 
K2D3 online tools, k2d3.ogic.ca) (Louis-Jeune et al. 2012). 
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Table 33. Predicted secondary structure content of PpADI variant M31 before and after PEGylation. 
 α helix β strand 
PpADI M31 65.96% 5.11% 
PEGylated PpADI 
(PEG: ADI=1:20) 
66.84% 5.07% 
PEGylated PpADI 
(PEG: ADI=1:50) 
66.20% 5.19% 
 
5.3.3. Selection of Arg residues to be mutated to Lys residues 
To improve the PEGylation efficiency of PpADI and thereby improved its half-life in blood 
circulation and the efficacy of PpADI as an anti-cancer agent, several arginine positions were 
selected for mutating to lysine due to arginine and lysine sharing similar biophysical properties 
(arginine and lysine are positively charged basic amino acids under physiological conditions and 
have similar pKa values and length of their side chains) (Sokalingam et al. 2012). This procedure 
of selection included three defined selection criteria in silico (Figure 35): i) accessible surface 
area of the side chain of arginine > 90 Å2, ii) the relative changes in folding free energy (∆∆GFoldX) 
< 2 kcal/mol, iii) the predicted pKa value of the new generated lysine residue should be lower 
than the reference  pKa (10.76, under YASARA parameters). Initially, 30 arginine residues were 
found at one subunit of PpADI M31. The substitutions C30R, K37R, K312R H404R were identified 
as beneficial substitutions from several directed evolution campaigns, therefore these positions 
are not selected for the further analysis as well as the residue R400 which is a catalytically 
important residue (see section 4.3.2). Eight positions were selected after the step 1 because the 
SASA of these arginines is larger than 90 Å2 which ensure the mPEG molecule has enough space 
for binding. Subsequently, after calculating of ∆∆GFoldx values, 6 positions (∆∆GFoldx < 2 kcal/mol) 
were selected which indicated that these substitutions will not cause a decrease in stability of 
the overall fold. Furthermore, the pKa values of these six mutated residues were predicted by 
YASARA. Out of six positions, the final four positions (R299, R319, R338, R382) were selected 
due to the lower pKa values as compared to reference pKa of lysine (predicted pKa value > 
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reference pKa suggested at least one negative amino acid is close to it and they can form a salt 
bridge with strong H-bonds). 
 
Figure 35. The selection procedure of arginine residues to be mutated to lysine residues for PEGylation (SASA > 90 Å
2
, ∆∆G
FoldX
 < 
2 kcal/mol, and predicted pKa value < the reference pKa (10.76)).  
5.3.4. The modification ratios of Lys of PpADI M31 and variants after PEGylation 
PpADI M31  was identified as the most improved PpADI variant with significantly reduced S0.5,app 
values (0.17 mM) and increased catalytic activity (v∆c,app = 3.096 μM·s
-1) at the physiological 
arginine concentrations (100 µM arginine) (Table 19). PpADI M32 (M31+R299K), PpADI M33 
(M31+R319K), PpADI M34 (M31+R338K), PpADI M35 (M31+R382K) were generated by SDM and 
the average molecular weight of PEGylated PpADI M31 and variants were calculated by 
ExperionTM automated gel electrophoresis system. Predicted number of PEG molecule attached 
to Lys was calculated by this equation: Number = [MW of (PpADI-mPEG-SS) – MW of (PpADI, 46 
KDa)] / MW of (mPEG-SS, 20 KDa). The calculated PEG molecule number was increase from 3 
(PpADI M31) to 3.6 (M31+R299K) and 3.8 (M31+R382K), which indicated the PEGylation 
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efficiency increased by introduction of substitution R299K and R382K into PpADI M31 (Figure 
36). 
 
Figure 36. (a) Experion gel of M31+R299K, M31+R338K, M31+R319K, and M31+R382K after PEGylation reaction (b) The average 
molecular weight of PEGylated PpADI M31 and variants were calculated by Experion automated gel electrophoresis system. 
5.3.5. Kinetic analysis of non-PEGylated PpADIs and PEGylated PpADIs 
The kinetic data of KM and kcat values of non-PEGylated PpADIs and PEGylated PpADIs were 
summarized in the Table 34. The KM values of PEGylated PpADIs are in the range of 0.24 mM to 
0.29 mM, which is slightly higher than those of non-PEGylated PpADIs, which suggested that the 
attached PEG molecules on the surface of the enzyme did not significantly reduce the affinity 
for the substrate. Furthermore, the kcat values of PEGylated PpADI variants (PpADI-PEG20) were 
found to be lower when compare to non-PEGylated PpADI variants, but it still retained at least 
70% of the non-PEGylated PpADI enzymatic activity under the physiological conditions (Table 
34). 
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Table 34. Kinetic constants (kcat and S0.5) of PpADI M31 (parent) and variants M32 (M31+R299K), M33 (M31+R319K), M34 
(M31+R338K), M35 (M31+R382K) which were calculated based on the sigmoidal model by using the Hill equation. 
PpADI S0.5  [mM] kcat [S
-1
] PEGylated PpADI S0.5 [mM] kcat [S
-1
] 
PpADI M31 0.22 21.8 PEG-PpADI M31 0.24 16.1 
PpADI M32 0.24 20.3 PEG-PpADI M32 0.26 14.4 
PpADI M33 0.25 19.8 PEG-PpADI M33 0.26 15.5 
PpADI M34 0.24 20.1 PEG-PpADI M34 0.29 15.1 
PpADI M35 0.23 21.2 PEG-PpADI M35 0.27 14.8 
 
5.3.6. Thermal resistance profile of non-PEGylated and PEGylated M31 and variants 
The thermal resistance of non-PEGylated and PEGylated PpADI M31, M32 (M31+R299K), M33 
(M31+R319K), M34 (M31+R338K), M35 (M31+R382K) were assessed by measuring their 
residual activity after heat treatment for 4 h, at varied temperatures from 30 to 80 °C. The half-
inactivation temperature (Tm) values of non-PEGylated PpADI varaints were found to be similar 
in the PBS buffer (from 45 °C to 46 °C) or in human serum (from 38 °C to 42 °C) (Table 35). 
After the PEGylation, the Tm values of all PEGylated PpADI were increased as compared to non-
PEGylated ADIs (Table 35). The most thermal resistant variants, PpADI M32 and PpADI M35, 
showed 11 °C and 10 °C higher than their non-PEGylated form in PBS buffer, respectively. 
Moreover, these two PEGylated variants also exhibited highest thermal stability in human 
serum (M32: 58 °C and M35: 55 °C). 
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Table 35. Tm values of PpADI M31 (parent) and variants M32, M33, M34, M35 in PBS buffer and human serum 
Non-PEGylated 
PpADI 
Tm [°C] 
in PBS buffer 
Tm [°C] 
in human serum 
PEGylated pADI Tm [°C] 
in PBS buffer 
Tm [°C] 
in human serum 
PpADI M31 46 40 PEG-PpADI M31 52 54 
PpADI M32 45 42 PEG-PpADI M32 56 58 
PpADI M33 45 41 PEG-PpADI M33 53 54 
PpADI M34 45 39 PEG-PpADI M34 52 50 
PpADI M35 46 38 PEG-PpADI M35 56 55 
 
5.3.7. Long-term measurements to determine thermal resistance of non-PEGylated and 
PEGylated PpADI M31 and variants 
The half-lives of PpADI M31 to M35 were determined by incubation of non-PEGylated and 
PEGylated PpADI at 37 °C. Notably, significant differences in half-lives (activity retention) were 
observed (Table 36). All the PEGylated PpADIs displayed longer half-lives compared to non-
PEGylated ADIs. Importantly, PEG-PpADI M32 and PEG-PpADI M35 have the longest half-lives of 
~3.5 days and ~3.6 days, which are ~1.6 and ~1.7 days longer than that of parent M31 in the PBS 
buffer. Furthermore, the half-lives of PEGylated M32 and M35 exhibited >2 days more than the 
non-PEGylated PpADIs (PEGylated M32: 3.9 vs. 1.8 days; PEGylated M35: 4.1 vs. 1.9 days) in 
human serum. The results (from sections 5.3.4 and 5.3.5) demonstrated that PEGylated PpADIs 
have higher thermal resistance and surface engineering for efficient PEGylation (increase 
modification ratio of PEGylation) could further improve the thermal stability of PpADIs. 
Importantly, two substitutions (R299K and R382K) were identified as beneficial substitutions for 
higher PEGylation efficiency. 
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Table 36. Half-life values of PpADI M31 (parent) and variants M32 (M31+R299K), M33 (M31+R319K), M34 (M31+R338K), M35 
(M31+R382K) in PBS buffer and human serum 
Non-PEGylated 
PpADI 
Half-life 
in PBS buffer 
(day) 
Half-life 
in human serum 
(day) 
PEGylated 
ADI 
Half-life 
in PBS buffer 
(day) 
Half-life 
in human serum 
(day) 
PpADI M31 2.1 1.9 PEG-PpADI M31 2.9 3.2 
PpADI M32 2.3 1.8 PEG-PpADI M32 3.5 3.9 
PpADI M33 2.3 1.9 PEG-PpADI M33 3.0 3.1 
PpADI M34 2.2 1.7 PEG-PpADI M34 3.1 3.3 
PpADI M35 2.1 1.9 PEG-PpADI M35 3.6 4.1 
 
5.3.8. Stability test of PEGylated PpADI M36 (a combination of R299K and R382K) 
The aforementioned findings prompted us to combine of the two substitutions of R299K and 
R382K. The recombined variant PpADI M36 (M31+R299K+R382K) was obtained by introduce of 
an identified substitution R382K to PpADI M32. To investigate the thermal resistance of 
PEGylated PpADI M36, the Tm values and half-life values were detected of non-PEGylated and 
PEGylated PpADI M31 and M36 after incubation in human serum. PEGylated M36 exhibited the 
highest thermal resistant, which has a Tm value 10 °C higher than PEGylated M31 and 24 °C 
higher than non-PEGylated M31 and M36 (Table 37). In the first 2 days of incubation at 37 °C in 
serum, PEG-PpADI M31 and PEG-PpADI M36 showed very similar activity (Figure 37). After 2 
days, PEG-PpADI M36 retained ~80% of its activity, whereas non-PEGylated PpADI only retained 
~40% of its activity, respectively. During the days 2-6, PEG-PpADI M36 always showed 10-20% 
higher relative activity than PEG-PpADI M31. A comparison of half-lives at 37 °C in human serum 
showed that PEG-PpADI M36 has a half-life of ~4.8 days compared to ~3.2 day half-life of PEG-
PpADI M31 and the ~1.9 day half-life of PpADI M31 (Table 37). In addition, merely ~5% activity 
of PpADI M31 and M36 was preserved in human serum after 4 days, while PEGylated PpADI 
M36 showed over 30% residual activities on the day 7 (Figure 37). 
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Table 37. Half-life values of non-PEGylated PpADI M31 and PpADI M36 in human serum 
Non-PEGylated 
PpADI 
Tm in 
human serum 
[°C] 
Half-life 
in serum 
(day) 
PEGylated 
ADI 
Tm in 
human serum 
[°C] 
Half-life 
in serum 
(day) 
PpADI M31 40 1.9 PEG-PpADI M31 54 3.2 
PpADI M36 40 2.0 PEG-PpADI M36 64 4.8 
 
 
Figure 37. Thermal inactivation at 37 °C in human serum as determined through residual activity measurements of non-
PEGylated and PEGylated PpADI M31 and M36 after 1–7 days of incubation (Relative activity = specific activity of PpADI or PEG-
PpADI/ specific activity of PpADI M31, before incubation) × 100%.  
5.4. Discussion 
PEGylation of proteins have been established as an effective approach to overcome the 
application limitations of protein pharmaceuticals, e.g. decrease in immunogenicity of the 
enzyme and prolonged half-life. For example, Clark and co-workers reported the formulation of 
recombinant MaADI with mPEG-SS20 kDa for extended serum half-life from 4 h to nearly 7 days in 
mice, and a weekly dose of 5 IU could keep the serum arginine under detectable levels (Ensor et 
al. 2005). In this chapter, a new strategy to increase potential PEGylation positions (Lys residue) 
was developed. The validation of this strategy was performed on PpADI M31. Four Arg residues 
were replaced by Lys to increase the PEGylation efficiency. The average numbers of PEGylation 
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were increased from 3 (PpADI M31) to approximately 4 (PpADI M32 (M31+R299K) and M35 
(M31+R382K)) per subunit. Importantly, the resulting final variant PpADI M36 
(M31+R299K+R382K) exhibited improved long-term stability in human serum both of Tm value 
and of half-life. 
The increased stability of PEG-ADI is of great importance for their therapeutic applications, such 
as drug storage, delivery and activity retention. Previously, random PEGylation reactions were 
successfully used in most instances of already approved PEGylated products by reacts of PEG 
molecules with the Ɛ-amino side chains of lysine or the N-terminal α-amino group. Nevertheless, 
many of Lysine residues are buried in the protein where PEG molecules could not reach. 
Therefore, in principle, the number of PEGylated residues could be increased by protein 
engineering (increase the Lys residue numbers) and the resulting conjugates are expected to 
show higher thermal resistance. Surface exposed Arg residues were selected to be mutated to 
Lys rather than other amino acids, because Arg and Lys harbor similar biophysical properties: 
they both are positively charged basic amino acids under physiological conditions, have similar 
pKa values and length of their side chains (Sokalingam et al. 2012). The three newly proposed 
selection criteria (in silico) to target surface Arg residues represent a straight forward strategy to 
identify Arg residues which can preferentially be targeted for PEGylation by SDM to Lys 
residues. The first selection criterion (accessible surface area of the side chain of arginine > 90 
Å2) excluded Arg residues which are not exposed to the surface aims to avoid changing buried 
residues. It may would have a higher impact in protein structure and probably decrease protein 
stability. Thus, in a second step, ∆∆GFoldX was calculated and the substitutions (Arg to Lys) with 
the ∆∆GFoldX < 2 kcal/mol, which indicated that the substitution Arg to Lys at these positions will 
not lead to destabilizing effect. In the third step, Arg residues are preferred whose predicted pKa 
values were lower than the reference pKa (10.76) suggesting no negative amino acid is in close 
proximity. In principle, this approach can also be applied to other therapeutic enzymes (such as 
arginase and asparaginase) for predict the potential PEGylation sites. 
One PpADI M31 subunit consists of 30 Arg residues, out of which five Arg residues were 
excluded due to their higher impact in enzyme structure and activity. There are eight Arg 
residues’ SASA more than 90 Å2, wherein six substitutions resulted in a ∆∆GFoldX less than 2 
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kcal/mol. Only four of them are fulfilling all three selection criteria. The thermal stability of 
these four PEGylated variants has been investigated under physiological conditions. Two of the 
generated PEGylated variants M32 and M35 (R299K and R382K) showed increased thermal 
resistance when compared to PEGylated PpADI M31 (Table 35 and Table 36).  
Due to the extent of improvements, the variants M32, M35 were selected to detailed 
characterization in terms of enzyme kinetic parameters and thermal resistance improvements 
(Table 34, 35 and 36). PEG-PpADI M32 showed 11 °C and 10 °C higher Tm values than their non-
PEGylated forms in PBS buffer and human serum, respectively. PEG-PpADI M35 displayed 10 °C 
and 17 °C higher Tm values than their non-PEGylated forms in PBS buffer or human serum, 
respectively. Furthermore, among the four PEGylated variants with single mutation, these two 
PEGylated variants (PEG-PpADI M32 and PEG-PpADI M35) exhibited higher thermal stability in 
PBS buffer and human serum (M32: 57 °C and M35: 55 °C). Moreover, the two PEGylated M32 
(R299K) and M35 (R382K) also exhibited the longest half-lives in PBS buffer and human serum 
during the long-term stability test. Therefore, R299K and R382K were finally identified as 
beneficial substitutions for increasing the PEGylation efficiency. 
The final PEGylated variant PpADI M36 (combine two benefical substitutions of R299K and 
R382K) exhibited the highest thermal stability. Its Tm value is 10 °C higher than PEGylated M31 
and 24 °C higher than non-PEGylated M31 and M36 (Table 37). Significant differences of non-
PEGylated and PEGylated PpADI M36 in activity retention were observed after 2 days of 
incubation at 37 °C (Figure 37). PEG-PpADI M36 retained ~80% of its activity, whereas PpADI 
M36 only retained ~40 % of its activity, respectively. A comparison of half-lives at 37 °C showed 
that PEG-PpADI M36 has a half-life of ~4.8 days compared to ~3.2 day half-life of PEG-PpADI 
M31 and the ~1.9 day half-life of PpADI M31 (Table 37). The average numbers of PEGylation 
sites were increased from ~12 (PpADI M31) to ~20 (PpADI M36) suggesting that substitutions 
R299K and R382K indeed resulted in more efficient PEGylation. 
To the best of my knowledge, among all the PEGylated ADIs, only three PpADI bioconjugates 
(PpADI-SS20 kDa, PpADI-SC20 kDa, PpADI-SPA20 kDa) have been evaluated in the context of and Tm 
and half-life values in plasma (Zhang et al. 2014). Other studies were more focus on the 
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pharmacodynamics and pharmacokinetic of ADIs in mice models, which could not be directly 
compared to our data. The PEGylated PpADI M36 showed ~15 °C higher than all the three 
PEGylated PpADI M13-3 (64 °C vs ~50 °C). Importantly, the PEGylated PpADI M36 also exhibited 
more than 1 day longer half-life of ~4.8 days than PpADI M13-3 (~3.5 days) (Figure 3E in the 
reference of Zhang et al. 2014). Therefore the PEGylated PpADI M36 is a highly attractive 
candidate to be used as for the treatment of arginine-auxotrophic melanomas. The three-step in 
silico approach for increasing PEGylation sites can be used for other ADIs or other therapeutic 
enzymes. 
5.5. Conclusions 
In conclusion, a novel protein engineering approach (three-step in silico approach), independent 
to other methods, was developed to quickly identify potential amino acid substitutions that 
could result in enhanced PEGylation efficiency. In this study, out of the four selected 
substitutions, two substitutions R299K (M32) and R382K (M35) indeed contributed to enhanced 
thermostability of PEG-PpADI in human serum. The PEGylated PpADI M36, combining R299K 
and R382K, exhibited further improved Tm values (64 °C) and half-life values (4.8 days) in human 
serum, compared to PEGylated PpADI M31 (54 °C and 3.2 days). This study suggested the 
thermal resistance of PEGylated enzymes, could be improved by surface engineering to increase 
the PEG sites. Since the proposed strategy is in theory independent of the protein/enzyme class, 
it is likely that other therapeutic enzymes such as arginase and asparaginase can also be 
modified using this approach for increase the PEGylation efficiency and half-life of the 
PEGylated form of enzyme. 
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Summary and Conclusions 
The main focus of this thesis entitled ‘‘Protein engineering of a therapeutic enzyme arginine 
deiminase’’ was on methodological advancements in screening system for directed PpADI 
evolution at physiological arginine concentrations (100-120 µM in blood plasma) and surface 
engineering to improve PEGylation efficiency for prolonged half-life of PpADI.  
In chapter II, a coupled screening system in MTP format was developed for a continuous 
detection of ammonia with linear detection range between 5 and 300 µM. The ammonia 
detection-based continuous ammonia detection system (ADS) was validated in two directed 
evolution campaigns yielding PpADI variants with significantly lowered S0.5 value and IC50 value 
for two human melanomas cell lines. Moreover, the anti-proliferation activity of the improved 
PpADI variant M19 was investigated and compared to WT and M6 by in vitro experiments with 
two relevant melanoma cell lines under physiological conditions. For example, the IC50 values 
for G361 dropped from 4.85 (WT) to 0.12 (M6) to 0.05 μg/mL (M19). Furthermore, the 
screening system based on ammonia detection can be used to improve other ADIs and very 
likely also other enzymes which produce ammonia, such as amidase or nitrilase. 
Furthermore, a flow cytometry screening platform to evolve enzymes for efficient operation at 
low substrate concentrations was described in chapter III. This screening platform employs a 
ligand-mediated eGFP-expression system (LiMEx) which relies on a competitive 
conversion/binding of arginine between arginine deiminase and arginine repressor an effector 
molecule. The intensity of the eGFP fluorescence serves as a quantitative measure of enzymatic 
performance. Arg-LiMEx was validated by screening of ~8.2x106 clones in three iterative rounds 
of epPCR libraries. The improved PpADI variant M31 showed a significant inhibitory effect 
against SK-MEL-28 and G361 melanoma cell lines (IC50 = 0.02 μg/mL for SK-MEL-28 and G361). 
Importantly, the competitive selection principle of LiMEx is not limited to arginine and can very 
likely be extended to other metabolites or compounds in which a repressor is activated at a low 
concentration. 
Summary and Conclusions 
 Page 102 
 
In chapter IV, in order to elucidate the important function of two loops in modulating the 
substrate affinity of PpADI, loop engineering and structure/sequence comparison were 
performed on two loops in which four amino acid positions were identified to be beneficial for 
reducing the ‘KM’ (S0.5) value of PpADI. A hypothesis was proposed, after analysis of the MD 
simulation results, that the high flexibility of the side chain of gating position 400 (increased 
RMSD and RMSF values) is beneficial for arginine conversion at low concentration likely due to 
less efficient blocking of the active site. Furthermore, investigation of possible amino acid types 
on position 43 showed that polar and uncharged residue is preferred at position 43 when 
methionine is at position 400. The variants L6 (M6+R400M+D43S) and L10 (M31+R400M+D43S) 
exhibited lower S0.5 values (0.19 mM and 0.17 mM). The RMSD of M400 increased from 0.44 
(PpADI M6) to PpADI 0.62 (PpADI L6), and RMSF increased from 1.30 (M6) to 1.66 (L6). This 
strongly suggested that the more flexible of the side chain of the residue at position 400, the 
lower the S0.5 values of PpADI is.  
Finally, in chapter V, a novel three steps in silico approach was developed to quickly identify 
potential amino acid substitutions on the surface of PpADI that could result in enhanced 
PEGylation efficiency. Using this approach, surface engineered PpADI with more Lys residues for 
PEGylation displayed enhanced thermal resistance and prolonged half-life in serum. After 
PEGylation, the final variant PpADI M36 (M31+R299K+R382K) exhibited significantly improved  
Tm values (64 °C) and half-life values (4.8 days) in serum compared to the parent M31. The 
proposed three steps in silico approach is in theory independent of the enzyme classes. 
Therefore, it is likely that other therapeutic enzymes such as arginase and asparaginase can also 
be modified for increase the PEGylation efficiency by using this approach. 
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